Dried whole plant Artemisia annua as a novel antimalarial therapy by Elfawal, Mostafa A
University of Massachusetts Amherst 
ScholarWorks@UMass Amherst 
Doctoral Dissertations Dissertations and Theses 
Summer November 2014 
Dried whole plant Artemisia annua as a novel antimalarial therapy 
Mostafa A. Elfawal 
UMASS, Amherst 
Follow this and additional works at: https://scholarworks.umass.edu/dissertations_2 
 Part of the Entomology Commons, Medicinal Chemistry and Pharmaceutics Commons, and the Other 
Chemicals and Drugs Commons 
Recommended Citation 
Elfawal, Mostafa A., "Dried whole plant Artemisia annua as a novel antimalarial therapy" (2014). Doctoral 
Dissertations. 183. 
https://doi.org/10.7275/sd09-6c78 https://scholarworks.umass.edu/dissertations_2/183 
This Open Access Dissertation is brought to you for free and open access by the Dissertations and Theses at 
ScholarWorks@UMass Amherst. It has been accepted for inclusion in Doctoral Dissertations by an authorized 
administrator of ScholarWorks@UMass Amherst. For more information, please contact 
scholarworks@library.umass.edu. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dried whole plant Artemisia annua as a novel antimalarial therapy 
 
A Dissertation Presented 
By 
 
Mostafa Ahmed Elfawal 
 
 
 
Submitted to the Graduate School of the 
University of Massachusetts Amherst in partial fulfillment of the requirements for the 
degree of 
 
DOCTOR OF PHILOSOPHY   
 
September 2014 
 
 
 
Entomology 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© Copyright by Mostafa A. Elfawal 2014 
All Rights Reserved 
 
 
 
 
 
 
 
 
 
Dried whole plant Artemisia annua as a novel antimalarial therapy 
 
A Dissertation Presented 
By 
 
 
 
Mostafa Ahmed Elfawal 
 
 
 
 
 
Approved as to style and content by:  
 
_________________________________________________  
Stephen M. Rich, Chair  
 
 
_________________________________________________  
Anne Averill, Member  
 
 
_________________________________________________  
John Burand, Member  
 
 
_________________________________________________  
Michele Klingbeil, Member  
 
 
 
 
 
_____________________________________________  
                                     
                                     John Lopes, Microbiology Department Head  
                                                       
 
 
 
 
 
 
 
 
 
 
 
DEDICATION 
 
 
To my parents, my wife and my kids  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	  	   v	  
 
 
ACKNOWLEDGMENTS 
 
 
 
 
I would like to thank my advisor, Stephen Rich, for his great guidance and 
support.  I also thank Pamela Weathers and Doug Golenbock for their fruitful 
collaborations. Thanks are also due to Guang Xu for his sincere support. I would also like 
to thank the members of my committee, Anne Averill, John Burand and Michele 
Klingbeil for their helpful guidance during all stages of this project.  
I want to thank UMass Center for Clinical and Translational Science for funding this 
research.  
Many thanks are due to Evan Palmer-Young and all members of Laboratory of 
Medical Zoology for their help in this project. Thanks to my family and friends for their 
mutual support and encouragement to continue progressing during all stages of my 
academic study. 
 
 
 
 
 
 
 
 
 
 
 
	  	   vi	  
 
ABSTRACT 
DRIED WHOLE PLANT ARTEMISIA ANNUA AS A NOVEL ANTIMALARIAL 
THERAPY 
 
SEPTEMBER 2014 
 
MOSTAFA AHMED ELFAWAL, B.Sc., AIN SHAMS UNIVERSITY 
 
M.S., AIN SHAMS UNIVERSITY 
 
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST 
 
Directed by: Professor Stephen M. Rich 
 
Malaria is one of the worst vector-borne parasitic diseases in the developing 
world. The World Health Organization (WHO) estimated that 215 million cases of 
malaria occurred, with >655,000 deaths; half the world’s population is at risk of 
contracting the disease. Drugs are primary weapons for reducing malaria in human 
populations. Successful drugs are highly efficacious and inexpensive to manufacture 
synthetically. However, emergence of resistant parasites has repeatedly curtailed the 
lifespan of each drug that is developed and deployed. Currently, the most effective anti-
malarial is artemisinin, which is extracted from the leaves of Artemisia annua. Due to 
poor pharmacokinetic properties and prudent efforts to curtail resistance to 
monotherapies, artemisinin is prescribed only in combination with other anti-malarials 
composing an Artemisinin Combination Therapy (ACT). Low yield in the plant, and the 
added cost of secondary anti-malarials in the ACT, make artemisinin costly for the 
developing world. As an alternative, we compared the efficacy of oral delivery of whole 
plant (WP) A. annua to a comparable dose of pure artemisinin in a rodent malaria model. 
We found that WP reduces parasitemia at least five fold more effectively than a 
	  	   vii	  
comparable dose of purified drug, slows the evolution of malarial drug resistance in 
Plasmodium chabaudi infected mice, and is effective against already resistant 
Plasmodium yoelii (ART). This increased efficacy may result from the increase in the 
bioavailability of artemisinin in the blood of mice fed the whole plant, in comparison to 
those administered synthetic drug. When accompanied by plant material, more 
artemisinin enters the blood stream, demonstrating a beneficial effect of the plant matrix 
on the bioavailability of artemisinin.  Increased efficacy and resilience against drug 
resistance may result from the synergistic benefits of other anti-malarial compounds in A. 
annua, such as flavonoids and terpenoids. Although effective against Plasmodium, 
neither WP nor artemisinin and artesunate are effective against Babesia microti. The 
differential response of B. microti and Plasmodium to artemisinins is likely the result of 
significant differences in their cell biology and metabolism of hemoglobin.  Well-
tolerated, and compatible with the public health imperative of forestalling evolution of 
drug resistance, inexpensive, locally grown and processed whole plant A. annua therapy 
might prove to be an effective addition to the global effort to reduce malaria morbidity 
and mortality. 
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GENERAL INTRODUCTION 
 
For centuries, plant based therapies dominated medical practices in the ancient 
civilizations of Africa, Asia and South America and till today in many parts of the world 
where western medicine is scarce and herbal remedies are the only effective means to 
treat or prevent diseases (1). Modern, Western medicine dismisses these therapies for the 
most part as arcane remnants of a pre-enlightened era of modern drug design.  From this 
predominant reductionist world view, therapies lacking precise explanation of the 
interaction of chemical moieties are not to be trusted. But like all reductionist reasoning, 
this view unnecessarily simplifies the complexity of the problem and ignores the context 
by which herbal remedies—not to mention the plants from which they are derived—have 
evolved.  In the present study, we present empirical evidence of superior efficacy of an 
herbal remedy that outperformed it pseudo-pharmaceutical counterpart, which is the 
primary favored anti-malarial drug at this moment.  We explain this observation in the 
proper evolutionary context, demonstrate the propensity for the herbal therapy’s 
increased resilience, and outline a new paradigm that leverages rather than ignores 
cultural and evolutionary history.  
Plants possess defensive physical barriers including their cuticle and cell walls 
that help them to avoid being overcome by herbivores and pathogens. Despite such 
physical barriers, some pathogens have developed invasion mechanisms to penetrate into 
plant’s inner tissues through wounds and/or stomata. Parasitization puts selection 
pressure on these plants to evolve more advanced and complex chemical defenses to 
overcome infection. In turn, plant chemical defenses puts selection pressure on pathogens 
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to evolve counter-resistance mechanisms that circumvent plant defenses.  This creates the 
circumstance of classical “arms race”, and this particular interaction between plants and 
pathogens is one of the oldest evolutionary conflicts in nature.  In plants, this has lead to 
evolution of complex array of chemical defenses.  
Plants and animals have faced similar microbial enemies throughout their 
evolutionary histories and through convergence they have evolved similar systems of 
innate immunity whereby host cell receptors detect pathogen-associated molecular 
patterns and activate defense responses (2).  Studies on plants, humans, mice and insects 
revealed evolutionary conservation in recognition of Pathogen-Associated Molecular 
Patterns (PAMPs) by extracellular Pattern Recognition Receptors (PRRs) across 
kingdoms (3, 4). The general elicitors of innate immunity in vertebrates—
lipopolysaccharides, peptidoglycan, eubacterial flagellin, unmethylated bacterial DNA, 
glucans, chitins, and mannans—comprise the same set of molecules known to elicit plant 
defense responses (3-7). 
To defend against pathogens, early land plants developed PRRs to recognize 
PAMPs and activate PAMP-Triggered Immunity (PTI). Through millions of years of 
interaction with pathogens, plants have been able to detect and recognize molecular 
patterns that are highly conserved across a broad range of microbes and essential to 
pathogen survival, such as lipopolysaccharide, peptidoglycan, flagellin (a flagellum 
protein), chitin, and fungal ergosterol (8). The recognition of PAMP's by PRR's activates 
PTI through a suite of activations and inductions that results in transcription of defense 
genes. The results of these transcriptional changes include physical effects such as callose 
deposition, cell death, stomatal closure (9, 10) as well as chemical effects including 
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production of reactive oxygen intermediates, antimicrobial proteins, and antimicrobial 
secondary metabolites. 
PAMPs are conserved and indispensible epitopes for which mutations tend to be 
deleterious, hence microbes evolved resistance mechanisms by secreting effector proteins 
that suppress PTI in their host plants (4, 9, 10). Effector proteins are diversely produced 
by vast variety of microorganisms including bacteria, fungi, and viruses.  Effector 
proteins are essential for pathogen invasion, growth and development since they 
enzymatically target plant cells to modify defense proteins leading to escape from host 
recognition. In response to effector proteins, plants have evolved specialized Effector 
Triggered Immunity (ETI) such as pathogen-Resistance (pR) proteins that recognize 
microbial effector proteins and/or detect pathogen-induced modification of self-proteins. 
pR proteins activate pathways that are ultimately responsible for a plant's pathogens-
resistance phenotype, including production of further synthesis of a repertoire of 
antimicrobial secondary metabolites.  
The evolution of secondary metabolites 
The evolutionary rate in microorganisms is greater than in comparatively long-
lived plants. How do plants overcome such a disadvantage in evolutionary rate? One 
means of overcoming fast evolving microorganisms is by the evolution of somatic broad-
spectrum pR proteins that detect any damage or modification in PTI-associated proteins. 
Such indirect interaction with microorganisms enabled several pR proteins to provide 
protection against a diverse group of pathogens (2).  
Another strategy that enables plants to compensate for their lower evolutionary 
rate is the continuous evolution, generation and retention of secondary metabolites. In 
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contrast to primary metabolism where high specificity of enzymes is favored to reduce 
costs associated with the production of non-essential end products (11), fitness 
advantages may be conferred for producing enzymes of secondary metabolism with 
lower specificity (10).  To be effective, secondary metabolites must randomly intercalate 
into essential and conservative enzyme sites found in a broad range of microorganisms, 
hence the ability interact with multiple substrates is favored (12).  
To offset costs of maintaining such diverse and non-specific secondary 
metabolism, plants have catalytic flexibility in which one enzyme is able to produce 
many products from one substrate (11). Such catalytic flexibility enabled plants to 
generate exceedingly diverse repertoires of secondary metabolites that play important 
roles in plant defense against microorganisms. Examples of such catalytic flexibility are 
found in sesquiterpene biosynthesis in which one enzyme produces 34 different products 
from a single substrate while in another instance the enzyme produces 52 products from a 
single precursor (11). Through evolution, plants have acquired a matrix of antimicrobial 
secondary metabolites marked by synergism among its components (13, 14). Natural 
selection favors the sequential increase of metabolic diversity and retention of secondary 
metabolites units into the chemical matrix until the marginal cost of producing additional 
metabolites outweighs their benefits (15).    
Through their shared evolutionary history with microorganisms, plant and animal 
defense mechanisms have been refined against conserved and functionally indispensable 
components of microorganismal pathogens. Plant and animal immune systems evolved 
independently but in parallel given the commonality of the microbial pathogens in their 
aim. These parallels have resulted in some remarkable convergences, and it is therefore 
	  	   5	  
not surprising that some of these defenses evolved in one kingdom should prove 
efficacious against microbial agents targeting the other kingdom.  This conserved 
evolution is the basis and rational for a new approach to developing therapies to combat 
human pathogens.  In particular, we assert that certain plant secondary metabolites, which 
evolved to protect against plant pathogens, provide the basis exploring novel therapies 
against human pathogens.   
Animals Self-medication 
Many animal species may exploit the antimicrobial properties of plant secondary 
metabolites for use against their own pathogens through evolved self-medication 
behavior. Self-medication is innate behavior in many insect species including the fruit 
fly, honeybee, wooly bear caterpillar and monarch butterfly (16). Using medicinal plants 
against microorganisms reduces the animal’s immunity costs through reliance on the 
plant’s matrix of antimicrobial secondary metabolites (16, 17). Self medication behavior 
in humans and non-human animals may be explained by two hypothesizes, social 
learning and natural selection (18).  
Here we define self-medication in an infectious system as the circumstance where 
none species (self-medication host) is infected by a second species (pathogen) and ingests 
a third species (typically a plant) in direct response to that infection.  To consider self-
medication behavior as an adaptation arising by natural selection several conditions must 
be met.  
1. Host must ingest a the material (eg. plant) in direct response to infection, 
2. Ingestion should not occur in uninfected host individuals, 
3. Ingestion must increase the fitness of infected hosts relative to infected host that 
do not ingest, and 
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4. Behavior must be innate and heritable; i.e. not learned through classical 
reinforcement or taught through social interactions. 
The presumptive targets of this natural selection are the physiological aspects of 
sensory reception, eg. taste and olfaction.  For example animals seek sodium containing 
substances using specific appetite for sodium that is immediate and requires no 
experience of previous deficiency. Such behavior appears innate and totally taste-guided 
(19).  Analogous of salt-taste marker, medicinal plants generally have distinctive volatile 
fragrance, rough surface and bitter taste that may serve as cues for animals adapted to 
self-medicate (20, 21). Many plant antimicrobial secondary metabolites are often 
distasteful and bitter taste that also may be used as taste marker (18). Hart (2005) 
reviewed the taste of a range of medicinal plants and found the majority of them have 
bitter or astringent taste (18).  Generally mammals dislike and reject bitter dietary foods, 
hence the shift in taste receptors to tolerate (or even prefer) bitterness upon infection, 
could be the specific adaptation responsible for self-medication.  Examples of this 
stringent model of adaptation are limited, but there are tantalizing glimpses such as the 
observation that sick chimpanzees were unable to detect bitter substrate inserted into their 
food while healthy ones were able to detect the bitter taste and rejected such food (22).   
Because, infection associated with disease causes dramatic changes in the 
physiology and/or the behavior of infected individual, natural selection could favor the 
condition in which sick individuals deviate from their regular diet if such dietary 
deviation gives a direct fitness advantage.  This could occur either by behavioral changes 
that drive sick individuals to ingest non-regular diet or by physiological changes that 
thwart their sensory capability to discern and/or avoid bitter plants (18). This model 
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fulfills the first two requirements for demonstrating self medication behavior as adaptive.  
The actual conditions under which this would occur nonetheless require a balance of 
complex trade-offs since the aversion to bitter taste is presumably an adaptation itself to 
avoid toxicity.  Therefore, subduing that protective behavior must lead to anti-pathogenic, 
anti inflammatory, immunomodulatory, or analgesic benefits that outweight risks of 
intoxication from the medicinal source or other non-medicinal, bitter tasting diet items.  
 
Chimpanzees and bonobos use medicinal plants such as Veronica spp. to treat 
gastrointestinal illnesses and Aspilia spp., Rubia spp. and Manniophyton spp. to expel 
internal worms (16). Baboons use Balanites spp. to control schistosomiasis (23). Wood 
rats and starlings use Umbellurlaria spp. and Agrimonia spp. to kill nest-borne fleas and 
mites, respectively (24).   Neanderthals used herbal remedies to treat diseases and to 
manipulate disease symptoms about 60,000 years ago (18).  
From this view we may speculate that animals' anti-microbial defenses against 
microorganisms evolved in the presence of medicinal plants, so that animals lacking 
assistance from the matrix of plant secondary metabolites would not have optimal 
defenses. In this sense, use of single–compound pharmaceuticals against pathogenic 
microorganisms may actually relax challenges to those microorganisms trying to evolve 
ways of circumventing barriers to their proliferation.   
To be certain, herbal remedies based upon plant secondary chemistries should not 
be accepted as efficacious without rigorous evaluation.  However they also should not be 
discounted out-of-hand simply because they were not designed from a modern 
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biochemical perspective nor even when they may possess emergent properties that defy 
our specific ability to identify their mechanisms.   
Study Systems 
Parasitic protists in the phylum Apicomplexa are a large group specialized in 
parasitizing animal cells. They use the unique apical complex structure, for which the 
phylum is named, to penetrate host cells. Apicomplexan parasites are of great importance 
to society because they are the causative agents for many of human and domestic animal 
diseases. The phylum includes parasites of humans (Plasmodium, Babesia, Toxoplasma, 
Cryptosporidium, Isospora), and domesticated animals (Theileria, Babesia, Sarcocystis, 
Neospora, and Eimeria).  
Among apicomplexan parasites, malaria is the worst vector-borne parasitic 
disease in the developing world. The World Health Organization (WHO) estimated that 
215 million cases of malaria occur each year, with >655,000 deaths; and half of the 
world’s population is at risk of contracting the disease (25). Only five species of 
Plasmodium parasites are known to infect humans: Plasmodium falciparum, P. vivax, P. 
ovale, P. malariae, and P. knowlesi. Among the five species, P. falciparum is the most 
deadly and responsible for more than 90% of annual deaths, followed by P. vivax. 
Humans contract the disease after being bitten by female anopheles mosquitoes, which 
release the infectious sporozoites into circulating blood where they travel to the liver and 
invade hepatocytes. Within the hepatocytes, the parasite begins asexual replication (exo-
erythrocytic schizogony), producing thousands of small merozoites that each invade a 
single red blood cell (RBC) and start the erythrocytic schizogony, producing about 20 
small merozoites each. After maturation, the infected RBC's rupture, releasing the new 
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merozoites to invade new RBCs. These erythrocytic cycles result in the majority of 
malaria disease symptoms including anemia, fever, headache, splenomegaly, and hepatic 
and renal dysfunction. In falciparum malaria, the parasites export parasitic proteins to the 
surface of infected red blood cells, causing them to block small capillaries in the infected 
patient’s brain, resulting in neurological symptoms, coma, and sudden death (26). Some 
merozoites develop into sexual gametocytes within RBC's. If the patient is bitten by 
another mosquito, these gametocytes are imbibed with the bloodmeal. Once in the 
mosquito’s midgut, the male and female gametocytes fuse together, forming motile 
zygotes that penetrate the midgut wall and settle in the basal lamina, forming oocysts. 
Within the oocysts, the parasite undergoes asexual replication, producing thousands of 
sporozoites. Mature oocysts rupture, releasing thousands of sporozoites into the 
mosquito’s hemolymph. From the hemolymph, sporozoites migrate to the insect's 
salivary glands, from which they infect human hosts when the mosquito next feeds.  
Like Plasmodium, Babesia invades erythrocytes, has an invertebrate vector, and 
the symptoms of the two diseases are similar, including fever, flu-like symptoms, chills, 
headache, anemia, hemoglobinuria, and myalgia. In regions where malaria is endemic, 
co-infection with Babesia parasites have been observed, and babesiosis may be 
misdiagnosed as malaria (27). To date seven species of Babesia have been found to cause 
human babesiosis Babesia microti, B. divergens, B. bovis, B. canis, B. duncani, B. 
venatorum and Babesia KO1 (28).  Babesia has infected increasing numbers of humans 
in recent years due to greater medical awareness and increased numbers of 
immunocompromised patients (28). Among all Babesia spp., B. microti causes most of 
human cases in United States (28). 
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Antimalarial chemotherapy 
The fight against malaria predates the discovery of its causative agents. Periodic 
fevers associated with swamps and marches have been known since Hippocrates and 
were treated with herbal remedies. Two main herbal remedies, cinchona bark and 
qinghao (Artemisia annua), were used to treat malaria for hundreds of years. In western 
countries, cinchona bark has been known to treat swamp fever since 1640. In 1820, 
quinine was isolated from cinchona bark and used to treat malaria-like fever. Quinine was 
the first purified compound used against human disease (29). In the 1880's, the causative 
agent of malaria was discovered, although the role of the anopheles mosquito in malaria 
transmission was not discovered until the 1890's.  
The fight against malaria entered a new era in which synthetic compounds were 
used to combat parasites. In the1890's, Paul Ehrlich successfully treated two malaria 
patients using methylene blue and launched his "magic bullet" concept, the idea that a 
chemical compound could be made which selectively targeted a disease-causing 
organism. Methylene blue was the first synthetic compound to be used against human 
disease (29). Ehrlich’s "magic bullet" concept was embraced in the search for new 
remedies for malaria. Some sixteen thousand synthetic compounds were tested against 
malaria parasites, but very few were effective against malaria (29). In 1934, chloroquine 
was developed and used in the fight against malaria. Chloroquine was both safe for 
humans and very effective against malaria parasites. Around that time, many purified and 
synthetic compounds were employed to treat human diseases, with herbal and natural 
remedies falling out of mainstream medical use.   
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In the 1950's the WHO launched the Global Malaria Eradication Program 
(GMEP), through which they hoped to eradicate malaria parasites using two main 
synthetic compounds, chloroquine as an antimalarial and Dichloro Diphenyl 
Trichloroethane (DDT) as an insecticide against mosquitos.  Chloroquine was used on a 
wide scale as prophylactic treatment. However, although chloroquine was highly 
effective, it lacked resilience against drug resistance. The emergence and spread of 
chloroquine resistant malaria parasites and DDT resistant mosquitos were the main 
reasons for the demise of GMEP in the 1960's.  
Malaria parasites were among the first pathogenic organisms to develop drug 
resistance against curative agents. After chloroquine’s failure, many antimalarial 
compounds were deployed as monotherapy against malaria parasites; unfortunately, the 
effectiveness of each of these treatments was compromised by the emergence of drug-
resistant parasites.  
In the 1970's artemisinin was isolated from A. annua and found to be effective 
against malaria parasites resistant to chloroquine. In spite of its activity in fighting 
malaria parasites, artemisinin has low pharmacokinetic properties. To increase its 
pharmacodynamic and pharmacokinetic properties and to slow the evolution of drug 
resistance, the WHO recommended using artemisinin derivatives, mainly artesunate, in 
combination with other antimalarial drugs. The low yield in A. annua and the additive 
cost of partner drugs make the WHO-endorsed Artemisinin-based Combination Therapy 
(ACT) unaffordable for many people in developing countries. It was hoped that use of 
ACT would minimize risk of drug resistance. However, in 2005, the earliest evidence of 
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P. falciparum resistance to ACTs was found in Southeast Asia (30-34). The fight against 
malaria became critical again, as no affordable replacement for ACT was available. 
Hypothesis 
Plants have evolved complex matrices of secondary metabolites—produced as a 
response of PTI and ETI upon recognition by PAMPs and pR proteins respectively—that 
target conserved functions, and structural elements of invading microorganisms and 
animal herbivores.  Such broad-spectrum defense is observed in many medicinal plant 
species for which the secondary metabolites matrix that has broad biological activity 
against multiple taxonomic groups. For example, in A. annua and artemisinin are known 
to have activity against bacteria, protozoa, viruses, arthropods, and other plant species 
(35-39). Synergism between the biological activities of artemisinin and other A. annua 
secondary metabolites results in a range of ecological effects, from allelopathic activity 
against other plants to antimalarial activity against animal disease.     
A. annua is regarded as safe for human consumption and has been widely 
consumed in many parts of China for more than 2000 years (29) and was a known herbal 
treatment for fevers symptomatic of malaria (40). Recently, several reports have 
described synergism between artemisinin and other A. annua flavonoids.  These include 
antimalarial activity of A. annua constituents other than artemisinin-- including other 
terpenes and flavonoids-- and increased bioavailability of artemisinin when delivered in 
plant form. Based on such reports, we hypothesized that the complex matrix of secondary 
metabolites present in the dried whole plant A. annua material may be used directly 
against malaria parasites, thereby saving the high cost associated with artemisinin 
isolation and purification. Because A. annua has been successfully used to treat malaria-
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like fevers for more than 2000 years without development of resistance, and because of 
the multiple constituents in A. annua known to have antimalarial activity, we also 
hypothesized that dried whole plant A. annua may be used to treat malaria parasites 
resistant to artemisinin and to delay the evolution of drug resistance.  
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Introduction: 
Malaria is among the most prevalent infectious diseases in the developing world, 
imposing a vast burden of mortality and perpetuating cycles of poverty. In 2009, the 
World Health Organization (WHO) estimated that 225 million cases of malaria occurred, 
with >780,000 deaths (42). In spite of recent advances in our understanding of this 
parasite, efforts to prevent transmission have remained largely unchanged for over a 
century. Though malaria vaccines hold future promise, vector control and chemotherapy 
remain the primary weapons for reducing the burden of disease in individuals and 
populations. Artemisinin, in the form of Artemisinin-based Combination Therapy (ACT), 
is currently the best treatment option against those malaria parasites that have evolved 
resistance to drugs such as chloroquine (43). Moreover, artemisenin (AN) and its 
derivatives have also been shown to have effects on a number of viruses, a variety of 
human cancer cell lines (35, 36), several neglected tropical parasitic diseases including 
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schistosomiasis (44), leishmaniasis (45, 46), New- and Old-World trypanosomiases (47), 
and many livestock diseases (48). 
Current artemisinin production requires its extraction from the cultivated herb 
Artemisia annua L., which as an herb is “generally regarded as safe” (GRAS) for human 
consumption (49). However, considerable production costs and limited availability of 
artemisinin limit its present usefulness in the campaign against malaria (50). De novo 
chemical synthesis of artemisinin is neither practical nor cost-effective, and even the best 
plant cultivars yield only ca. 1.5% artemisinin, and agricultural yields seldom exceed 70 
kg/ha (51). The drug is solvent-extracted from plant material, crystallized, and typically 
used for semi-synthesis of artemisinic derivatives. Although A. annua is relatively easy to 
grow in temperate climates, low yields of AN lead to relatively high costs for isolation 
and purification of the drug (52). Because of this shortcoming, plant scientists have 
focused their efforts on producing cultivars of A. annua with higher artemisinin crop 
yield (53). Transgenic production schemes are also underway (54, 55). Meanwhile, a 
worldwide shortage fails to meet the need to treat malaria, not to mention those other 
diseases against which artemisinin holds such promise (43).  
One means of reducing the cost of production would be to limit the amount of 
post-harvest processing by using the whole plant (WP). We wondered whether omitting 
the extraction step, by using whole plant A. annua directly as the source of artemisinin, 
might prove efficacious in an experimental murine model. In a previous study, we 
showed that mice fed dried WP material had about 40 times more artemisinin in their 
bloodstream than mice that were fed a corresponding amount of pure drug (49). This 
amount exceeded by eight fold the minimum concentration of serum artemisinin required 
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for a single curative dose (10 µg/L) against P. falciparum (56). This suggested that the 
active ingredients were delivered faster, and in greater quantity, from whole plant 
treatments than from pure drug treatments. We further hypothesized that because of the 
combination of parasite-killing substances (artemisinin and flavonoids), perhaps 
augmented via synergism among the constituent compounds in this plant (artemisinin and 
the flavonoids: casticin, eupatorin, and chrysosplenetin) (57, 58), might render whole 
plant consumption as a form of ACT.  
We thus sought to determine whether WP A. annua can kill malaria parasites in 
vivo using a rodent malaria model.  Plasmodium chabaudi is an excellent model for the 
most deadly of the human parasites, P. falciparum, because both species demonstrate 
preference for mature erythrocytes as opposed to reticulocytes that are favored by other 
human and rodent malaria parasites (59, 60). Rodent malaria models are invaluable for 
studying modes and mechanisms of resistance to antimalarial compounds (61). 
Demonstrating parasite killing using this inexpensive and resilient treatment could be an 
important first step in establishing a novel therapy based on WP A. annua for treatment of 
human malaria.  Furthermore, it may help to identify complementary and/or synergistic 
anti-malarial compounds within the plant.  
Materials and Methods 
Plant material. Artemisia annua L. (SAM cultivar; voucher MASS 00317314) 
containing 1.48±0.06% AN (dry weight) was used in this study. To obtain adequate 
amounts of leafy biomass, plants were grown in soil either in greenhouses, culture rooms, 
or growth chambers under continuous light to maintain vegetative growth. Plants were 
propagated by cuttings to insure that the outcrossing characteristics of A. annua did not 
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result in genetic loss of AN content. When the plants reached about 0.5-1 m, they were 
harvested and dried in the light at 25°C for several days. Leaves were then stripped from 
stems and pulverized through a series of brass sieves ending with 600 µm meshed 
powder. All dry leafy biomass was pooled, homogenized and then assayed for AN.  
AN was measured using GC-MS by extracting with pentane (~6 mg/mL) and 
sonicating for 30 min. Extract was decanted into glass test tubes and dried under nitrogen 
gas, then stored at -20°C until analysis. Samples were resuspended in pentane and 
transferred to a 1 mL vial with a 100 µL glass insert. A 1 µL injection into the GC-MS 
[GC, Agilent 7890A; MS, Agilent 5975C; column, Agilent HP-5MS (30 m x 0.25 mm x 
0.25 µm)] used the following oven program: ion source temperature 280°C; inlet 250°C; 
initial temperature of 125°C for 1 min, then ramp to 300°C at 5°C/min, for a total time of 
36 min. Ultrapure helium was the carrier gas at 1 mL min-1. Identification was via NIST 
library and purchased AN standard (Sigma-Aldrich Chemical, St. Louis, MO).  
Parasite information. Plasmodium chabaudi ASS (MRA-429) was obtained through the 
Malaria Research and Reference Reagent Resource Center (MR4) as a part of the BEI 
Resources Repository, NIAID, NIH. Tubes of blood collected from infected mice, were 
removed from liquid nitrogen storage and left at room temperature for 30 minutes. A 
100µL aliquot of the parasite-infected blood was mixed with 500 µL Dulbecco’s 
Phosphate Buffered Saline (DPBS). To recover parasite stocks, two C57BL/6 mice were 
injected intraperitoneally (i.p.) with 200 µL of the DPBS mixture. Percent parasitemia 
was determined in Giemsa-stained thin blood smears days 3-7 post-infection (p.i.). Seven 
days after infection, one mouse was euthanized and cardiac puncture was used to collect 
blood into lithium heparin tubes. Infected blood was volumetrically adjusted by dilution 
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in DPBS to create a 200 µL aliquot of 105 infected erythrocytes for infection into two 
additional mice for a second round of recovery. The recovered parasites were used for 
subsequent challenge and drug study. Rodent malaria models showed differences in the 
degree of susceptibility among different strains of mice, as well as age related 
differences. We used two mice to draw the standard parasitemia curve in the C57BL/6, 8-
12 weeks male mice. The two mice were inoculated i.p with 105 infected erythrocytes and 
parasitemia was determined in Giemsa-stained thin blood smears from day 1 to day 11 
p.i. (Fig. I.1). P. chabaudi produces a self-limiting infection in laboratory mice, such that 
parasites began to appear in the blood smears on day 4 p.i., reaching peak of the 
parasitemia on day 8 p.i. From the standard parasitemia curve we chose to treat mice on 
day 6 p.i. when the parasites commenced the log phase of growth.  
Mouse feeding and drug delivery details. All mouse experiments used inbred male 
mice C57BL/6, 12 weeks of age. For each experimental replicate, an aliquot of 105 
infected erythrocytes was inoculated i.p. into each of 30 mice. For the first two replicates, 
mice were randomly divided into three groups of ten mice per group (ANLO, WPLO, and 
Control). For the third replicate, mice were randomly divided into five groups of six mice 
per group (ANLO, WPLO, ANHI, WPHI, and Control). Individual mice were identified by 
tail markings using permanent marker. Starting on day 3 p.i., percent parasitemia was 
determined in Giemsa-stained thin blood smears from a drop of peripheral blood obtained 
from the tail. Mice were observed twice daily for signs of disease stress. Food and water 
were introduced ad libitum for the first five days. On day five, food was withheld for 24 
hours, but water was freely available.  
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Whole plant (WP) treatment consisted of dried A. annua plant powder ground and 
passed through a 0.3 mm sieve, mixed with water to a final volume of 0.5 mL. Two 
dosages were used: WPLO and WPHI. WPLO consisted of 0.5 mL treatment slurry 
contained 40 mg dry weight (DW) of plant powder, containing 600 µg artemisinin and 
corresponding to 24 mg AN/kg live body weight. WPHI consisted of 0.75 mL treatment 
slurry contained 200 mg DW of plant powder, containing 3000 µg artemisinin and 
corresponding to 120 mg AN/kg live body weight. 
Pure drug (AN) treatment consisted of artemisinin purchased from Sigma Aldrich 
freshly dissolved in DMSO and pulverized mouse chow. Two dosages were used, ANLO 
and ANHI. ANLO consisted of a slurry containing 600 µg AN dissolved in 60 uL DMSO 
mixed with water and 40 mg powdered mouse chow to final volume of 0.5 mL. ANLO 
consisted of a slurry containing 3000 µg AN dissolved in 60 uL DMSO mixed with water 
and 200 mg powdered mouse chow to final volume of 0.75 mL.  
Placebo control (CON) consisted of 60 µL DMSO, mixed with water and 40 mg 
powdered mouse chow to a final volume of 0.5 mL. Delivery of the appropriate 0.5 mL 
treatment/control was performed immediately after dose preparation by oral-gastric 
gavage into mice using a feeding needle (18G, curved, 2”, and 2.25 pall diameter). Food 
and water were introduced ad libitum after gavage. Percent parasitemia was determined 
every 24 hours in Giemsa-stained thin blood smears from days 3-6 p.i., then every six 
hours for 48 hours post gavage, and again on 24 hour intervals for days 9-11 p.i.. All 
mice were euthanized on day 11 p.i. via asphyxiation in a CO2 chamber followed by 
cervical dislocation. The experiment was repeated three times. 
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Statistical analyses. We fit linear mixed models to estimate and compare the average 
parasitemia for each treatment group at each measured time point. Including a random 
intercept for individual mice allowed us to adjust for repeated observations on the same 
mouse. The primary analysis compared CON, WPLO and ANLO treatment groups to assess 
statistically significant parasitemia differences in these groups at each time point (see Fig. 
I.2). For the primary analysis, data from all three replicates were used. A secondary dose-
response analysis compared the CON, WPLO, WPHI, ANLO, and ANHI treatment groups at 
all measured time points (see Fig. I.3). For the secondary analysis only data from the 
third replicate were used.  
For each model, 10,000 Markov chain Monte Carlo (MCMC) samples were 
drawn from the posterior distributions of the average parasitemia levels for each 
treatment group at each time point. Then, 95% confidence interval endpoints for a 
particular parasitemia level were established at the 2.5th and 97.5th quantiles of the 
MCMC samples for that parameter. An estimated difference between two groups was 
declared “significant” if the 95% confidence interval for the difference did not cover 
zero. Analyses were conducted using the statistical software R v2.15(62) and the lme4 
package(63), Graphics were produced using the ggplot2 package. 
Ethics Statement. This study was carried out in strict accordance with the 
recommendations in the Guide for the Care and Use of Laboratory Animals of the 
National Institutes of Health. The protocol was approved by the Institutional Animal Care 
and Use Committee (IACUC) of the University of Massachusetts (Protocol# 2011-0015). 
All efforts were made to minimize suffering of animals during experimental procedures. 
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Results and Discussion 
We found conclusive evidence that whole plant A. annua kills malaria parasites 
more effectively than a comparable dose of pure drug. In our primary analysis, we 
compared parasitemia over time in mice treated with either low-dose, whole plant A. 
annua (WPLO), low-dose, pure drug artemisinin (ANLO), or placebo (CON). Only 24 hr 
after treatment, dead parasites (with condensed dark pigment) were observed in mice 
treated with WPLO ; 30 hours after treatment, parasitemia was < 0.001% (Fig. I.1). Mice 
treated with WPLO showed significantly lower parasitemia than those treated with ANLO 
from 12 to 72 hours post-treatment (Fig. I.2). Mice treated with ANLO did not show 
significant difference in parasitemia from those administered a placebo at any time point.  
In a subsequent dose-response analysis, we added high-dose comparison groups, 
ANHI and WPHI.  Each of the four treatment groups experienced significantly lower 
parasitemia than the control mice (Fig. I.3). All mice treated with WPLO responded 
strongly in the first 24 hrs following gavage, showing the lowest level of parasitemia at 
30 hours pos-gavage; only 3 of 26 WPLO-treated mice (12%) had parasitemia of 3% or 
greater.  However, 36 hours after gavage, 38% of the WPLO-treated mice were above this 
threshold. Notably, treatment with WPLO was just as effective in reducing parasitemia as 
was treatment with ANHI for the first 72 hours post treatment (Fig. I.3). Thereafter, 
WPLO-treated mice had significantly higher parasitemia. Although the suppression of 
parasitemia was significant in the three treatment groups after a single dose treatment, 
low dose WPLO resulted in faster recrudescence than either WPHI or ANHI (Fig. I.3), 
suggesting that multiple treatments at this dose would be necessary for a curative effect. 
Considering that a normal course of ACT treatment for human malaria currently requires 
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several doses, spread over several days, a similar regime may also be effective in the case 
of lower dose WP administration. Pharmacokinetics will be needed to determine serum 
levels of the drug. No differences between the WPHI and ANHI groups were detected after 
treatment. This is consistent with the short half-life seen in the pure drug in human 
patients and the prescribed need for multiple doses per day for several days (42). 
 
Although the precise mechanisms of its anti-malarial activity remain unproven, 
artimisinin is suspected (like other drugs, including chloroquine) to interfere with heme 
detoxification, a crucial requirement for parasite survival in erythrocytes. Plasmodium 
parasites digest hemoglobin, producing heme as a byproduct. Free heme molecules are 
toxic, so parasites sequester it in the form of hemozoin polymers in unique digestive 
vacuoles. Artemisinin is a sesquiterpene lactone with a crucial endoperoxide bridge (64), 
and in the presence of heme, this bridge is broken, thereby releasing free radicals harmful 
to the parasite (65).  
The empirical evidence for increased anti-malarial activity of WP relative to AN 
might be explained by differential bioavailability of the artemisinic compounds.  
Weathers et al (2011) showed that mice treated with a WP equivalent of 1.2 mg/kg AN 
reached their highest concentration of artemisinin in the blood (87 µg /L) 30 min after 
gavage, whereas mice treated with AN did not reach their the maximum concentration 
(74 µg /L) until much later ( ≥ 60 min) (49).  Moreover, poor solubility and high 
metabolic breakdown of artemisinin by hepatic and intestinal cytochrome P enzymes 
(CYP P450 and CYP3A4) may reduce its bioavailability when administered in pure form 
(66). Infusions made from whole plant A. annua showed marked inhibition of the 
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intestinal and hepatic CYP enzymes by flavonoids and/or other compounds (48). Hence, 
inhibition of metabolic enzymes correlates with greater bioavailability of artemisinin, 
which is consistent with our findings that WP demonstrates greater parasite killing 
activity than a comparable pure drug treatment.  
Whole plant (WP) A. annua may also have enhanced antimalarial activity due to 
synergism among particular plant compounds and artemisinin (14, 48, 67). Among these 
compounds are many flavonoids, of which at least six (artemetin, casticin, 
chrysosplenetin, chrysosplenol-D, cirsilineol, and eupatorin) are of interest for their 
antimalarial roles. The synergism between artemisinin and these flavonoids may be due 
to their ability to potentiate the activity of artemisinin. When each of these six flavonoids 
was combined individually with artemisinin, the IC50 of AN against P. falciparum 
decreased by 20-50%, demonstrating an apparent synergy between the sesquiterpene 
lactone, artemisinin, and those six methoxylated flavonoids (57, 58). The precise 
mechanism of flavonoids in activating artemisinin is not fully understood, however it has 
been reported that A. annua  methoxylated flavonoids enhance the formation of the 
artemisinin-heme complex (68), which increases the release of free radicals. 
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Fig. I.1. Giemsa stained blood smears from mice showing erythrocytes infected with P. 
chabaudi, 30 hours after treatment with (A) WPLO (24 mg/kg whole plant delivered 
artemisinin), (B) ANLO (24 mg/kg pure drug artemisinin), and (C) Placebo control. 
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Fig. I.2. P. chabaudi parasitemia of three treatment groups across all experimental 
replicates: low-dose whole plant A. annua (WPLO, N=26 containing 24mg/kg in planta 
artemisinin, and low-dose pure drug (ANLO, N=20) containing 24mg/kg pure artemisinin, 
and placebo control (CON, N=23) which received only mouse chow. Dark lines indicate 
average parasitemia by treatment type. Lighter lines show individual mouse trajectories. 
Shaded regions indicate the 95% confidence interval for the means calculated based on 
normality assumptions. Dashed vertical line indicates time of treatment.  
 
Two other major A. annua flavonoids, myricetin and quercetin, are known to 
inhibit mammalian thioredoxin reductase, which is critical for cellular redox control (69). 
Thioredoxin reductase is also essential for the P. falciparum erythrocytic stage (70); 
therefore, inhibition of this parasite enzyme by myricetin and quercetin may work in 
synergy with artemisinin against P. falciparum (71). 
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Fig. I.3. Dose comparisons of WP and AN treatments from the third replicate 
experiment: WPLO (N=6) and WPHI (N=6) received 24 mg/kg and 120 mg/kg in planta 
artemisinin, respectively; ANLO (N=5) and ANHI (N=6) received 24 mg/kg and 120 
mg/kg pure artemisinin, respectively. Placebo control (CON, N=6) received only mouse 
chow. Dark lines indicate average parasitemia by treatment type. Lighter lines show 
individual mouse trajectories. Shaded regions indicate the 95% confidence interval for 
the means calculated based on normality assumptions. Dashed vertical line indicates time 
of treatment. 
 
In addition to the bioavailability and potentiation attributes of WP, there are other 
compounds in A. annua that may act to reduce parasitemia independent of artemisinin. 
Liu et al (1992) reported the antimalarial activity of several A. annua flavonoids 
delivered in vitro as isolated compounds, in the absence of artemisinin (58). Moreover, 
antimalarial activity has been documented for related plant species that do not produce 
artemisinin (72). Among the compounds in A. annua not yet fully investigated are more 
than a dozen other sesquiterpenes, some of which have shown promise for killing 
parasites in rodent models (67).  
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Determining the mechanisms for increased efficacy of WP will require further 
investigation, but it seems certain that the constituent compounds contained within A. 
annua comprise a complex set of interactions and synergies yet to be described. Given 
the complex nature of the plant and its many components, WP may not necessarily be 
considered a simple monotherapy.  While the temptation might be to consider WP as 
merely an alternative delivery mechanism for artemisinin, our results strongly indicate 
that WP is unique and may represent an innovative combination therapy. We refer to this 
as a plant Artemisinin Combination Therapy (pACT).  A pACT can be distinguished 
from other combinational therapies where the drug components do not necessarily work 
synergistically because their combinations are artificially contrived. The pACT comprises 
a biologically complex entity, in which the combinations are the result of evolutionary 
processes that would have attributes of redundancy and resiliency that make combination 
therapies selectively advantageous to simple monotherapies. Refinements of these 
combinations by evolutionary processes ensures they are robust.  
The novelty of the WP pACT cannot be overemphasized as there is a common 
misconception that this therapy has been tested previously. It has not. The WP therapy 
tested in the present study should not be confused with tea or infusion therapy. Whole 
plant A. annua (WP) tested here against murine malaria, utilizes the plant in its entirety, 
dried under controlled conditions and ingested by the host. Such a preparation of A. 
annua has never been tested against malaria parasites (in humans, mice or otherwise).   
Because A. annua has long been used to make tea to treat fever in Asia (73), 
several investigators have proposed to re-establish the use of A. annua tea for rapid 
treatment of malaria (43, 74). These teas have major shortcomings. Firstly, large volumes 
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of tea must be consumed over short periods to ensure adequate ingestion of drug, a 
nontrivial matter considering the bitter taste of the tea, especially for pediatric patients. 
Moreover, while a 5 min boiling water extraction yields about 90% of the plant’s 
artemisinin (74), this is not an effective process for extracting key flavonoids (58). 
Analysis of hot water tea extracts following the optimized protocol described by van der 
Kooy and Verpoorte (74), showed loss of about 99% of the original flavonoids that 
reportedly synergize with artemisinin (75).  
Not only does WP differ from teas and infusions in terms of its efficacy and 
pharmaceutical properties, but because of its preparation, it can be carefully controlled 
and preserved. We was previously proposed development of a new form of anti-malarial 
therapy based on dried, encapsulated A. annua leaves as an inexpensive, dose-controlled, 
rapid delivery of the drug to treat uncomplicated cases of malaria and other neglected 
tropical diseases for which artemisinin has been shown to be effective (49). Dosage can 
be controlled because dried WP A. annua can be homogenized and assayed for 
artemisinin content prior to encapsulation. Capsule size and number can be adjusted 
based on artemisinin content and patient weight.  
Our purpose in the present study was to determine whether this “generally 
regarded as safe” (GRAS) herb (76) is effective in killing malaria parasites in vivo. 
Extrapolating appropriate human dosage from experimental evidence in mouse models 
will require additional investigation, however it is generally understood that this 
extrapolation will not scale linearly with respect to body mass.   Better indicators that 
allow for allometry include use of total body surface area (77) and/or take full 
consideration of physiochemical properties of the drugs and species involved (78). As an 
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example of this non-linear relationship, we can look to the results from ANLO treatment 
administered to mice in this study.  ANLO mice received a dose of 24 mg/kg which 
exceeds the current WHO single therapeutic dose (20 mg/kg) for treating human malaria, 
however, in our study this dose of pure drug had very little effect against mouse malaria 
parasites.  This is most likely due to metabolic differences and rates of uptake of oral 
drug between mice and humans.   
Single oral dosages of AN proven effective against human P. falciparum malaria 
range from 100-500 mg (79), which corresponds to 6-33 grams of WP assuming a 1.5% 
artemisinin content.  Assuming an average tablet size of 1 gram, delivery of a comparable 
dose of WP seems plausible. However, our data suggest that WP requires a smaller 
overall amount of artemisinin since even the WPLO effectively reduced malaria after just 
a single dose.  Moreover, it is important to bear in mind that while WPLO was the lowest 
concentration in our study, it does not necessarily represent a minimum effective dose.  
Notwithstanding challenges to be overcome and further research needed, our 
preliminary investigations hold great promise for easing the burden of high cost and 
limited availability currently confronting use of artemisinin-based semi-synthetic 
derivatives. While production costs for pharmaceuticals are not generally made publically 
available, it is possible to estimate potential savings associated with using WP vs. AN by 
looking to the estimated efficiencies of processing AN from the plant.  Kindermans et al 
(80) estimate the yield for extraction and purification of drug from A. annua to be 50-
80% efficient. This is consistent with general understanding of downstream processing 
costs wherein product losses increase with the number of unit operations (unit ops) (81).  
All things being equal (eg. artemisinin content for a given cultivar), this would suggest a 
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20-50% savings realized by forgoing the extraction and purification steps, as would be 
the case for production of WP. An example of the steps involved in production of AN 
from whole plant is provided by de Vries et al (1999), and compared with steps for 
producing WP (82) (Fig. I.4). Current production of AN by extraction from A. annua has 
seven more unit ops than the single unit op associated with direct use of the whole plant, 
and this net loss in efficiency translates to higher costs per product unit (Fig. I.4). Given 
the multiplicative principle of downstream processing, even if each processing step has 
relatively high efficiency, the overall efficiency will be less.  For example, even if each of 
the seven additional steps for production of AN could be made 95% efficient, the overall 
efficiency would be merely 69.8%, which means less than three quarters of the starting 
material is realized as drug. Such a loss means a higher cost for the delivered drug.  This 
simple analysis does not even consider the additional costs for reagents, labor, and energy 
that are required for processing the extract (Fig. I.4), which de Vries et al (1999) 
estimated may comprise up to 22.9% of the total manufacturing costs(82). This 22.9% 
represents additional cost savings for the use of WP because those inputs are no longer 
required. 
And while our data are far from representing a clinical trial, they do provide 
preliminary indications that the WP therapy requires a far smaller dose than the 
corresponding amount of pure artemisinin.  Indeed, our experiments indicate that a dose 
of WP has a five-fold increase in anti-malarial activity over that of the corresponding 
amount of AN.  This increased activity per unit of plant mass not only affects the dosing 
regimen but also has profound economic impacts if the WP approach should prove useful 
on a large scale to treat human malaria.  
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Fig. I.4. Comparison of production processes for AN and WP demonstrated reduction in 
unit operations associated with use of whole plant as therapy. (Based on de Vries et al 
(1999)(82). 
 
Much work remains to determine feasibility and efficiency of bringing whole 
plant A. annua into the arsenal in the fight against malaria. Among the challenges to be 
faced are some botanical obstacles, not the least of which is that this plant readily 
outcrosses, making it difficult to maintain high artemisinin content in the plant using seed 
saving methods which are standard agricultural practice in the developing world. 
Moreover, to date all efforts at improving the A. annua crop have focused on plant 
breeding and growth methods to maximize artemisinin content and in so doing to 
increase efficiencies and drive down costs. The use of the whole plant as therapy may 
represent a paradigm shift in this regard, since it may well be the case that effectiveness 
of WP is not wholly dependent on artemisinin content. New plant breeding strategies 
would have to be considered to optimize plant performance and maximize efficacy.  But 
the potential for an inexpensive malaria therapy that by its very nature possesses great 
resilience to parasite resistance, makes this investment of effort well worth while. 
 
AN process: 
Dried leaves à Milling and homogenization à Extraction at 30-40°C 
à Crystallization à Filtration/washing  à Decolorization à 
Crystallization à Filtration à Drying at 55-60°C àAN à Assay 
 
WP process: 
Dried leaves à Milling and homogenization à AN àAssay 
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Conclusions 
We have demonstrated that orally delivered WP A. annua is an effective means of killing 
malaria parasites in a mouse model. An edible WP A. annua treatment approach could 
significantly increase the number of patients treated and at significantly less cost. In fact, 
our results suggest that the WP treatment is a more efficient delivery mechanism than the 
purified drug, which is both costly and inefficient. Because AN has such broad potential 
therapeutic power against many infectious agents (35), our approach would dramatically 
reduce the cost of healthcare not only in developing countries, but also in more developed 
nations. Furthermore, use of A. annua could be implemented locally: a plan for plant 
cultivation, processing, and drug content validation was described in an earlier report 
(49). This, in turn, could provide a broad socioeconomic stimulus for developing 
countries while making them less dependent on the West. 
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Chapter II 
PHARMACOKINETICS OF ARTEMISININ DELIVERED BY ORAL 
CONSUMPTION OF ARTEMISIA ANNUA DRIED LEAVES IS IN DIFFERENT 
FOR HEALTHY VS. PLASMODIUM CHABAUDI-INFECTED MICE.  
Pamela J. Weathers*a, Mostafa A. Elfawal*b, Melissa J. Towlera, George K. Acquaah-
Mensahc, Stephen M. Richb 
 
a Biology and Biotechnology, Worcester Polytechnic Institute, Worcester MA 01609; b Laboratory of 
Medical Zoology, Microbiology, University of Massachusetts, Amherst, MA 01003; c School of Pharmacy, 
Massachusetts College of Pharmacy and Health Sciences (MCPHS University), Worcester, MA 01608   
*Contributed equally to the work 
Author contributions: M.A.E., P.J.W., and S.M.R. designed research; M.A.E. performed the mouse-
parasite experiments; M.J.T. and P.J.W. grew plants and conducted all biochemical analyses; P.J.W. and 
G.A-M. analyzed data; M.A.E., P.J.W., M.J.T., G.A-M. and S.M.R. wrote the paper (83).  
 
Introduction 
Malaria is one of the worst vector-borne infectious diseases in the developing world and 
the World Health Organization (WHO) estimated that 215 million cases of malaria 
occurred, with >655,000 deaths; half the world’s population is at risk of contracting the 
disease (25). Artemisinin, delivered in combination with an alternate drug as 
Artemisinin-based Combination Therapy (ACT), is currently the preferred treatment 
against the disease in order to prevent emergence of drug resistance.  
 
Artemisinin (AN; Fig. II.1) is produced, extracted, and purified from the “generally 
regarded as safe” GRAS; (40) plant Artemisia annua L. (Asteraceae). The drug also has 
shown promise against a wide variety of human (84) and livestock diseases (85); many 
are common to the developing world. Although new sources of the drug are emerging 
from chemical synthesis (86) and engineered microbes (87), artemisinin is currently only 
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commercially available from A. annua with insufficient supply to treat malaria, let alone 
other artemisinin-susceptible diseases. To obviate emergence of drug resistance, ACT co-
drugs are also needed, which usually increases cost (88). 
 
Fig. II.1. Artemisinin (left) and deoxyartemisinin (right). 
 
In an effort to improve the efficacy of artemisinin therapy and lower cost, we recently 
showed that when delivered orally to Plasmodium chabaudi-infected mice, a single dose 
of dried leaves of A. annua quelled parasitemia at least fivefold more than an equal 
amount of the pure drug (41). Beyond the abnormalities associated with infection, 
analysis of blood toxicology showed no toxicity, results consistent with some human 
trials using dried A. annua leaves (89, 90). It was also previously showed that healthy 
mice fed dried A. annua leaves had > 40 times more artemisinin in their bloodstream than 
mice fed a corresponding amount of pure drug (49). The measured serum levels exceeded 
by eight fold the minimum concentration of artemisinin (~10 µg L-1) required for lethality 
against P. falciparum (56). Together these results suggested that more artemisinin was 
delivered from whole plant treatments than from the pure drug treatment. Indeed, in a 
recent simulated digestion study, > 50% of dry leaf-delivered AN was still available in 
the intestinal digestate (91). It is thought that besides artemisinin, the combination of 
other parasite-killing substances normally present in the plant (flavonoids, monoterpenes 
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etc.; (92); (57); (93); (94) may be responsible for the observed responses either by 
improving bioavailability and/or improving therapeutic efficacy. In short, the plant may 
itself be providing endogenous combination drugs with its artemisinin. We thus termed 
this a plant-based artemisinin combination therapy, hereafter referred to as pACT.  
 
To better assess the potential of pACT, we conducted a longer pharmacokinetic study to 
answer two main questions: were the pharmacokinetics of pACT different between 
healthy and infected mice, and was the plant matrix critical to the appearance of 
artemisinin in the blood? These results will further our understanding of how the drug 
moves into the blood when orally delivered as dried leaves of the whole plant.  
 
Materials and Methods 
Plant material. Artemisia annua L. (SAM clonal cultivar; voucher MASS 00317314; 
vernacular names: annual wormwood; qīnghāo; sweet annie, sweet wormwood) 
containing 1.48 ± 0.06% artemisinin (dry weight) as determined by GCMS was used in 
this study. Dried leaves of the SAM cultivar also contain monoterpenes (e.g., 0.21% 
(w/w) camphor, 0.007% eucalyptol, 0.037% α-pinene) and flavonoids (0.37% total). 
Plants were grown under controlled conditions, harvested, dried, and leaves sieved and 
pulverized as previously described (41). Homogenized dried leaf biomass was assayed 
for artemisinin and deoxyartemisinin using GCMS as described in Elfawal et al. (2012). 
Identification was via NIST library and purchased standards of artemisinin (Sigma-
Aldrich Chemical, St. Louis, MO) and deoxyartemisinin (Toronto Research Chemicals 
Inc.).  
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Mouse infection, feeding and drug delivery. Plasmodium chabaudi ASS (MRA-429) 
was obtained through the Malaria Research and Reference Reagent Resource Center 
(MR4) as a part of the BEI Resources Repository, NIAID, NIH. Infection of 20 inbred 
male C57BL/6 mice weighing an average of 23 g was established by intraperitoneal (i.p.) 
injection with 107 P. chabaudi-infected red blood cells as detailed in Elfawal et al. 
(2012). A second group of 20 of these same mice served as healthy controls. Infected 
(n=20) and healthy (n=20) mice received oral-gastric gavage of pACT treatment 
consisting of dried, powdered A. annua leaves in a water slurry, prepared fresh, and 
administered 72 hours post-infection (when parasitemia reached 2-3%) at an amount 
corresponding to 100 mg AN kg-1 live body weight as detailed in Elfalwal et al. (2012). 
Blood was collected by cardiac puncture from five infected and five healthy mice at each 
of 4 time intervals (15, 30, 60, and 120 min post-gavage). For additional serum 
comparisons, two groups of three healthy mice were individually treated with 100 mg kg-
1 of pure AN in DMSO and water per kg live body weight with or without mouse chow 
(Elfawal et al., 2012) and blood collected at 60 min post gavage. Because a preliminary 
study showed that serum AN was at best barely detectable when mice were fed the pure 
drug, blood from each group of mice was pooled prior to extraction and analysis. 
 
Blood extraction and analysis. Serum and red blood cells were separated by 
centrifugation at 5,000 x g for 10 min and both fractions were immediately stored at -
80°C until extraction. Samples were extracted overnight at room temperature with an 
equal volume of methylene chloride. Where necessary, extracts were filtered through a 
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0.45 µm filter to remove particulates. Extracts were dried under nitrogen gas at room 
temperature and the dried residue resuspended in a known volume of methylene chloride 
for analysis of artemisinin and deoxyartemisinin by GCMS. Analysis and identification 
using authentic standards was as detailed above for analysis of plant extracts.  
 
Statistical analyses. The locally weighted scatterplot smoothing (LOWESS) function 
was employed to generate a polynomial regression trend line for each of the kinetics plots 
(95). Similar results were obtained using the R PK package (96), which was used to 
compute the area under the serum concentration versus time curve (AUC). Specifically, 
functions relevant to the serial sampling design employed in this study were applied. 
Based on mean concentrations at the various time points, the method of residuals was 
used to estimate a first order elimination rate constant (and half-life) as well as a first 
order absorption rate constant. 
 
Ethics Statement. This study was conducted in strict accordance with the 
recommendations in the Guide for the Care and Use of Laboratory Animals of the 
National Institutes of Health. The protocol was approved by the Institutional Animal Care 
and Use Committee (IACUC) of the University of Massachusetts (Protocol# 2011-0015). 
All efforts were made to minimize suffering of animals during experimental procedures. 
Theory 
Oral consumption of dried leaves of A. annua is showing therapeutic promise (41, 89, 
90). In contrast to what is known for pure artemisinin, little is known about how the drug 
moves from orally ingested plant leaves (e.g. pACT) into the blood stream. Comparing 
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the pharmacokinetics of the plant-delivered drug and one of its most common metabolic 
products in the serum of healthy and infected animals will improve our understanding of 
artemisinin metabolism and help clarify how such a therapeutic could eventually be 
implemented.  
 
Results and Discussion 
Similar to a preliminary study that compared oral gavage of either pure artemisinin or 
dried A. annua leaves (pACT) in healthy mice (49), we fed pACT to healthy or P. 
chabaudi-infected mice and measured artemisinin and deoxyartemisinin in the serum for 
two hours post gavage (Fig. II.2). The same data are replotted in Fig. II.3 to depict the 
independent kinetics of artemisinin and deoxyartemisinin in healthy vs. infected mice. 
The first order elimination rate constant for artemisinin in pACT-treated healthy mice 
was estimated to be 0.80 hr-1, which corresponds to an elimination half-life (T½) of 51.6 
min as determined by the method of residuals (45 ± 5.75 via the PK package of Jaki and 
Wolfsegger, 2011), similar to that observed in rats by Niu et al. (1985)(97). The first 
order absorption rate constant was estimated at 1.39 hr-1. Cmax and Tmax were 4.33 mg L-1 
and 60 min, respectively (Table II.1). The area under the curve (AUC) for the length of 
this study was 299.5 µg·min mL-1. In contrast, the AUC for pACT-treated infected mice 
was significantly greater at 435.6 mg·min L-1 (Table II.1). 
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Fig. II.2. Pharmacokinetics of artemisinin and one of it metabolites, deoxyartemisinin in 
serum of healthy (right) and P. chabaudi-infected (left) mice. Mice (n = 4 - 6 per time 
point per treatment group) were orally gavaged with dried leaves of A. annua to deliver 
100 mg kg-1 body weight dose of artemisinin; bars show SE and * p < 0.05, *** p < 
0.001 via Student’s t- test. 
 
Fig. II.3: Pharmacokinetics of artemisinin (left) and one of it metabolites, 
deoxyartemisinin (right) in serum of healthy and P. chabaudi-infected mice. Mice (n = 4 
- 6 per time point per treatment group) were orally gavaged with dried leaves of A. annua 
to deliver 100 mg kg-1 body weight dose of artemisinin; bars show SE and * p < 0.05, 
*** p < 0.001 via Student’s t- test.  
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Serum levels of artemisinin in the infected mice continued to rise over the 120 
min of the study period (Fig. II.2), and as a result, the T½ was not determined; Cmax and 
Tmax were estimated at ≥ 6.64 mg L-1 and ≥ 120 min, respectively. The key 
pharmacokinetic descriptors are shown in Table II.1 and are consistent with those of an 
earlier preliminary study using only healthy mice (49) and with other studies (97, 98) 
using rats fed pure artemisinin.  
 
Dose per animal 
(mg AN kg-1) 
Disease 
status 
# of subj.  
Artemisinin 
C max  
(mg L-1) 
T max  
(min) 
T ½  
(min) 
AUC 
(mg·min L-1) 
100 
100 
healthy 
infected 
4-6 
5 
4.33 ± 0.40 
≥ 6.64 
60  
≥ 120 
51.6  
nd 
299.5a  
435.6b 
Table II.1. Pharmacokinetic parameters for artemisinin after oral gavage of healthy or P. 
chabaudi-infected mice with pACT. Animals were fed A. annua dried leaves (pACT) to 
deliver 100 mg AN kg-1; average body weight was 23 g; nd, not determined. Letters a,b 
after AUC values indicate statistical difference at p ≤ 0.05; values are ± SE.  
 
Batty et al. (2008) compared the pharmacokinetics of dihydroartemisinic acid 
(DHA) in healthy and Plasmodium-infected mice that were administered a single 
intraperitoneal dose of DHA (100 mg kg-1) and found no significant difference in 
elimination half-lives. Since we was unable to determine T½ for infected mice in our 
experiment, we cannot compare it to healthy mice(99). Although a direct comparison 
cannot be made between the pharmacokinetics of DHA and artemisinin, in contrast to 
Batty et al (2008), healthy mice in our study had a significantly lower AUC than infected 
mice.
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Because it is one of several liver metabolic products of artemisinin, we also 
measured deoxyartemisinin (66). Like many other drugs, artemisinin is metabolized in 
the liver by cytochrome P450s including CYP2B6 and CYP3A4 (66), yielding a number 
of compounds including deoxyartemisinin, deoxydihydroartemisinin, 9,10-
dihydrodeoxyartemisinin, and a metabolite named crystal 7 that are found in human urine 
(100). Each of these degradation products lacks the endoperoxide moiety present in 
artemisinin, and is therefore therapeutically inactive (100). In contrast to its metabolism 
in healthy mice (Fig. II.2), metabolism of artemisinin to deoxyartemisinin appeared to be 
suppressed in the infected mice (Fig. II.2); infection retarded the capacity of the mice to 
form deoxyartemisinin from artemisinin over the two-hour study period. Overall, 
artemisinin concentrations decreased with a concomitant rise in deoxyartemisinin levels, 
but only in healthy subjects. In contrast, in infected mice artemisinin levels continued to 
rise over the study period whilst deoxyartemisinin levels fell and then remained constant. 
A. annua contains a diverse group of compounds (101) including flavonoids and 
monoterpenes that have been shown to inhibit P. falciparum (57, 92-94); many also have 
been shown to inhibit CYP3A4 (102-104).  
 
Results showed an initial dip in artemisinin levels at 15 to 30 minutes in healthy 
subjects, which we attributed at least partially to conversion of artemisinin to 
deoxyartemisinin (Fig. II.2). The metabolism of artemisinin to deoxyartemisinin appeared 
to be biphasic, declining slightly between 30 and 60 minutes, and then rising thereafter. 
The rising arm of the artemisinin pharmacokinetic profile in healthy mice occurred 
during this period of decreased metabolism to deoxyartemisinin; here, absorption 
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exceeded elimination. When Du et al (2012) measured deoxyartemisinin in healthy rats 
given a single oral dose of pure artemisinin (40 mg kg-1), the Tmax of deoxyartemisinin 
was 30-60 min longer than that of artemisinin (60 min)(98). Their artemisinin 
metabolism kinetics were the opposite of our results for a single oral dose of pACT 
where the peak of artemisinin was later than the first peak for deoxyartemisinin, but 
earlier than the second deoxyartemisinin peak (Fig. II.2). The pharmacokinetics in rats is 
not necessarily the same as in mice, so this may account for the differential response 
between our two sets of results.  
We also examined the effects of mouse chow on pure artemisinin entry into the 
serum. Mouse chow contains a variety of plant materials including soy, oats, wheat, 
alfalfa, beet pulp, corn, etc. No artemisinin was detected in the serum of mice fed 100 mg 
AN kg-1 body weight (Table II.2), a result consistent with the reported poor availability of 
the pure drug (105). When plant material was present either as mouse chow or A. annua 
pACT, the level of artemisinin in the serum rose to 2.44 and 4.32 mg L-1, respectively, 
indicating that the presence of plant material, even that in mouse chow, had a positive 
impact on the appearance of artemisinin in the blood (Table II.2). These results were 
consistent with preliminary study (49). A. annua leaves can contain as much as 1.4% 
(w/w) essential oils (101), which may enhance solubility and thus bioavailability of the 
nonpolar artemisinin molecule.  
 
For a human comparison, Giao et al. (2001) showed that when humans were 
given 500 mg oral doses of pure artemisinin (twice on day 1, then once thereafter for 
days 2-7), the level of recrudescence was 25%(106). In a summary of early human trials, 
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oral delivery of at least 600 mg per patient for 5 days was required to achieve ≤ 10% 
recrudescence (105). More recently a Kenyan clinical trial with four cohorts (4 x 12 
subjects) of malaria patients (90) showed that patients receiving dried A. annua leaf 
tablets containing 11.1 mg artemisinin (twice on day 1, so 22.1 mg d-1) followed by 7.4 
mg artemisinin (twice a day for days 2-6, so 14.8 mg d-1) had 9.1% recrudescence (107).  
 
Mouse treatment Artemisinin (mg L-1) 
Healthy untreated (3 pooled mice) a 0 
Healthy + 100 mg AN kg-1 (3 pooled mice) a 0 
Healthy + chow + 100 mg AN kg-1 (3 pooled mice) a 2.44 
Healthy + pACT at 100 mg AN kg-1 (n = 5) 4.33 ± 0.40b 
Infected + pACT at 100 mg AN kg-1 (n = 5) 3.78 ± 0.50b 
Table II.2. Artemisinin in serum 60 min post pACT or pure artemisinin gavage. 
a These mice were treated in groups of three; blood was harvested and pooled prior to 
extraction and measurement of artemisinin, so SE was not calculated. 
b Values are ± SE. 
 
Furthermore, increasing the amount of dried leaf tablets did not improve therapeutic 
response, suggesting that maximum effective dose had been achieved. Thus, although the 
patients treated with dried leaf tablets received about 3-4% the equivalent amount of pure 
artemisinin used in earlier studies (105, 106), they had an equal or better therapeutic 
outcome than patients treated with pure artemisinin. Those results are consistent with the 
results of this study.  
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Conclusions 
To our knowledge this is the first comparison between healthy and diseased animals of 
the pharmacokinetics of artemisinin and one of its liver metabolites, deoxyartemisinin, 
from orally delivered dried leaves of A. annua. When accompanied by plant material, 
more artemisinin enters the blood stream, demonstrating a beneficial effect of the plant 
matrix on the bioavailability of artemisinin. These results have implications for possible 
therapeutic use of pACT in treating malaria and other artemisinin-susceptible diseases.  
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Introduction 
The fight against malaria predates the discovery of its causative agent. For 
centuries malaria-associated fever was treated using herbal remedies. In the west, quinine 
(Cinchona bark extract) was the only affordable treatment against malaria until Paul 
Ehrlich’s magic bullet concept was adopted and thousands of synthetic compounds were 
tested against malaria parasites. Very few of these compounds were effective and safe for 
human use, but in the 1930’s chloroquine rose to ascendancy as a miracle cure for 
malaria (108). In the late 1950s, chloroquine was the main weapon when the World 
Health Organization launched the Global Malaria Eradication Program (GMEP).  
Development of drug resistant parasites and concomitant failure of chloroquine as the 
drug of choice lead to the eventual demise of GMEP by the close of the 1960s. Following 
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chloroquine’s failure, various antimalarial compounds were serially deployed one after 
another, and each unfortunately faced the same demise leaving millions of malaria 
patients without affordable treatment.   
In 1970s artemisinin was discovered as a pure drug extract from Artemisia annua. 
In wide scale clinical trials, artemisinin showed poor pharmacokinetic properties but 
nonetheless demonstrated potent antimalarial activity with a high safety profile (109).  It 
was determined that AN was best when used in combination with other antimalarial 
drugs, mainly mefloquine, which became known as Artemisinin Combination Therapy 
(ACT) (110).  It was hoped that use of ACTs would minimize risk of drug resistance.  
However, in 2005 evidence arose of P. falciparum resistant to ACTs in South East Asia 
(30-34, 111). The fight against malaria again entered another critical phase trying to 
avoid ACT from following chloroquine’s path towards obsolescence with no affordable 
replacement in sight. 
WHO has cautioned against use of non-pharmaceutical sources of artemisinin 
because of the risk of delivering sub-therapeutic doses that could exacerbate the 
resistance problem (112). This warning is valid given the low artemisinin content of most 
extractions and tea/infusions utilized for most non-pharmaceutical plant based therapies. 
However, in 2012 we demonstrated the efficacy of the whole plant—not tea, not 
infusion—as a malaria therapy and found it to be more effective than a comparable dose 
of pure artemisinin in a rodent malaria model (41).  We contend that Whole Plant (WP) 
A. annua therapy could provide a more abundant and affordable source of artemsinin-
based therapy by eliminating need for artemisinin extraction during manufacture.  
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WP is more effective than monotherapeutic artemisinin because WP constitutes a 
naturally occurring combination therapy that augments artemisinin delivery and 
synergizes its activity. This plant Artemisinin Combination Therapy (pACT) is the result 
of evolutionary refinement of the plant’s secondary metabolic products into a resilient 
and multi-component defense system.  As has been demonstrated for other combination 
therapies, we hypothesize that WP-based pACT will: (1) overcome existing resistance to 
monotherapeutic pharmaceutical artemisinin, and (2) increase the longevity of this 
therapy by delaying the onset of parasite resistance among wild types.  Here we’ve tested 
these two hypotheses in two mouse malaria models, artemisinin-resistant Plasmodium 
yoelii (ART) and artemisinin-sensitive Plasmodium chabudi chabaudi (ASS). 
 
 
Materials and methods 
 
Rodent Malaria Parasites: All experiments were performed using an appropriate rodent 
malaria model, obtained through the Malaria Research and Reference Reagent Resource 
Center (MR4) as a part of the BEI Resources Repository, NIAID, NIH. For long-term 
selection experiments, we chose P. chabaudi (ASS; MRA-429) because of its known 
susceptibility to WP and artemisinin treatment. P. yoelii (ART; MRA-421) was chosen as 
available an artemisinin-resistant strain (ART).  
Plasmodium chabaudi (ASS): Tubes of blood collected from infected mice, were 
removed from liquid nitrogen storage and left at room temperature for 30 minutes. To 
activate parasite stocks, two C57BL/6 mice were injected intraperitoneally (i.p.) with 200 
µL of infected blood. Percent parasitemia was determined in Giemsa-stained thin blood 
smears days 3-7 post-infection (p.i.). Seven days after inoculation, one mouse was 
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euthanized and cardiac puncture was used to collect blood into lithium heparin tubes. 
Infected blood was volumetrically adjusted by dilution in DPBS to create a 200 µL 
aliquot of 105 infected erythrocytes for infection into two additional mice for a second 
round of activation. The activated parasites were used in subsequent drug selection and 
resilience tests. 
Plasmodium yoelii (ART): To revive parasites after long-term storage in liquid nitrogen, 
two C57BL/6 mice were injected (i.p.) with 200 µL of infected blood. Seven days after 
infection to build up parasitemia, one mouse was euthanized and cardiac puncture was 
used to collect blood into lithium heparin tubes. Infected blood was volumetrically 
adjusted by dilution in DPBS to create a 200 µL aliquot of 107 infected erythrocytes for 
infection into four additional mice. Two mice were immediately treated with a dose of 
150 mg/kg AN recommended by the provider to activate and maintain resistant 
phenotype, while the other two mice were left untreated as controls. Seven days post 
inoculation, infected blood of one mouse, which first reaches 2% parasitemia from each 
group, was used in the next passage. Activation for AN resistant phenotype was repeated 
over 10 passages until the treated and untreated mice reached 2% parasitemia at the same 
time. The activated parasites were used in the subsequent challenge.  
Anti-malarial treatments. Artemisia annua L. (SAM cultivar; voucher MASS 
00317314) containing 1.48±0.06% AN (dry weight) was used in this study. Detailed 
information about plant material and AN analysis was reported in our previous work (41, 
83). To test dose dependent effects, we used two doses of each treatment such that the 
amount of artemisinin was equivalent in the two low (WPLO and ANLO) and the two high 
(WPHI and ANHI) treatment groups. 
	  49	  	  
Mouse feeding and drug delivery details: Each mouse in the WPLO and WPHI groups 
received 40 mg and 200 mg of dried A. annua plant powder corresponding to 24 mg 
AN/kg and 120mg AN/kg live body weight respectively. Plant powder was mixed with 
water to a final volume of 0.5 mL (WPLO) and 0.75 mL (WPHI). Each mouse in the 
artemisinin ANLO and ANHI groups received 600 µg or 3000 µg of AN (Sigma-Aldrich 
Chemical, St. Louis, MO) corresponding to 24 mg AN/kg and 120mg AN/kg, 
respectively, which was freshly dissolved in 60 µL of DMSO mixed with water and 
40mg or 200mg of powdered sieved mouse chow to a final volume of 0.5 or 0.75 mL, 
respectively. Placebo control (CON) consisted of 60 µL DMSO, mixed with water and 40 
mg powdered sieved mouse chow to a final volume of 0.5 mL. Delivery of the 
appropriate treatment/control was performed immediately after dose preparation by oral-
gastric gavage into each mouse using a feeding needle (18G, curved, 2”, and 2.25 pall 
diameter).  Individual mice were identified by tail markings using permanent marker. 
Percent parasitemia was determined in Giemsa-stained thin blood smears from a drop of 
peripheral blood obtained from the tail. Mice were observed twice daily for signs of 
disease or stress.  
Artemisinin resistant P. yoelii single dose response: An aliquot of 106 Plasmodium 
yoelii (ART) infected erythrocytes was inoculated i.p. into each of 30 C57BL6, 12 week 
old male mice weighing an average of 25 g, and were randomly divided into five groups 
(WPHI and ANHI, WPLO, ANLO, and CON) of six mice per group. Food and water were 
provided ad libitum for the first four days. On day four, food was withheld for 24 hours, 
but water was freely available. Mice were treated on day 5-post inoculation. Percent 
parasitemia was determined every 24 hours in Giemsa-stained thin blood smears for the 
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first four days post inoculation, then every eight hours for 48 hours post gavage, and 
again on 24 hour intervals for days 8-13 p.i. All mice were euthanized on day 13 p.i. via 
asphyxiation in a CO2 chamber followed by cervical dislocation.  
Artemisinin resistant P. yoelii curative treatment: An aliquot of 107 Plasmodium 
yoelii (ART) infected erythrocytes was inoculated i.p. into each of 12 DBA/2, 12 week 
old male mice, which were randomly divided into two groups (WPHI, ANHI ) of six mice 
per group. Starting on day 2 post-inoculation, each mouse in the WPHI and ANHI groups 
received 9 daily dosing of 200 mg plant material (corresponding to 120mg AN/kg) and 
3000 µg AN (corresponding to 120mg AN/kg) respectively. Percent of parasitemia was 
determined every 24 hours in Giemsa-stained thin blood smears from days 1-24 p.i., then 
every 72 hours for days 27-42 p.i. All mice were euthanized on day 42 p.i. via 
asphyxiation in a CO2 chamber followed by cervical dislocation.  
Selection for drug resistance and resilience test: Parasites were selected for resistance 
following the 2% relapse technique (113-115), in which a single treatment dose is given 
immediately after parasite inoculation to each mouse in the treated group, while a control 
group is inoculated and left untreated. The delay in reaching a 2% parasitemia in the 
treated group compared to the time required to reach the same parasitemia in the control 
group is the 2% delay time (113, 115). In each selection passage three groups of two mice 
were inoculated i.p. with 107 red blood cells infected with AN-sensitive Plasmodium 
chabaudi chabaudi (ASS). Mice used in selection for AN resistance received single dose 
of 2500 µg of AN corresponding to100mg/kg, on the other hand mice used in selection 
for WP resistance received 167 mg of WP material corresponding to100mg/kg AN in 
WP, while mice use as control received placebo. Gavaged materials were prepared as 
	  51	  	  
previously mentioned. Inoculations to the next passage occur on day 7 when all groups 
passed 2% parasitemia and build up enough parasitemia for the next passage. Seven days 
post inoculation, blood of one mouse, which first reaches 2% parasitemia from each 
group, was used in the following passage. On passage number 17 AN dose was doubled 
in the AN group after three consistent passages of zero delay time (AN treated group 
reachs 2% parasitemia at the same time as the control group). Parasites were considered 
resistant to a given dose if no delay time for three consequent passages.   Selection for 
WP resistance ended on passage number 48. 
Statistical analysis. We fit linear mixed models to estimate and compare the average 
parasitemia for each treatment group at each measured time point. Including a random 
intercept for individual mice allowed us to adjust for repeated observations on the same 
mouse. Single dose analysis compared the CON, WPLO, WPHI, ANLO, and ANHI 
treatment groups at all measured time points. 
For each model, 10,000 Markov chain Monte Carlo (MCMC) samples were 
drawn from the posterior distributions of the average parasitemia levels for each 
treatment group at each time point. Then, 95% confidence interval endpoints for a 
particular parasitemia level were established at the 2.5th and 97.5th quantiles of the 
MCMC samples for that parameter. An estimated difference between two groups was 
declared “significant” if the 95% confidence interval for the difference did not cover 
zero. Analyses were conducted using the statistical software R v2.15(62) and the lme4 
package(63), fig. III.1 was produced using the ggplot2 package. 
Ethics Statement. This study was carried out in strict accordance with the 
recommendations in the Guide for the Care and Use of Laboratory Animals of the 
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National Institutes of Health. All efforts were made to minimize suffering of animals 
during experimental procedures. 
 
 
Results and Discussion 
 
Previously, we found that dried whole plant A. annua kills P. chabaudi malaria 
parasites more effectively than a comparable dose of pure pharmaceutical artemisinin 
(AN). Here, we show that dried whole plant A. annua effectively kills malaria parasites 
resistant to artemisinin. Mice treated with single dose of WPHI (corresponding to 120 
mg/kg AN) showed significantly greater reduction in parasitemia than those treated with 
a single comparable dose of ANHI (120mg/kg) from 16 to 168 hours post-treatment (Fig. 
III.1). Mice treated with ANLO did not differ in parasitemia from those administered a 
placebo at any time point. Treatment with WPLO (corresponding to 24 mg/kg AN) was as 
effective as ANHI, despite the fact that ANHI dose contains 5 times more AN/kg (Fig. 
III.1). In these single dose studies, all parasite populations recrudesced around day 5 post-
treatment, which is typical of this parasite model. 
 To test whether WP can completely clear infection, we administered multiple 
dose daily treatment of WPHI corresponding to 120 mg AN/Kg/day for 9 consecutive 
days.  Multi-dose treatment reduced P. yoelii ART parasitemia below 2% for seven days 
post inoculation and to less than 1% from day 8 until complete clearance of parasitemia 
on day 14-post inoculation. Mice treated from both WP treatment groups were normal 
and did not show any signs of sickness. Infected groups of mice treated with comparable 
multiple doses of pharmaceutical AN (120mg AN/kg/day) for 9 days had mean 
parasitemia of 6% through day 7 with complete clearance on day 18-post inoculation 
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(Fig. III.2). Cured mice in WP and AN groups were monitored by Giemsa stained thin 
blood smears taken every 72 hours from day 24 until mice were euthanized on day 42 and 
no recrudescence was observed.  
 
 
Fig. III.1. AN-resistant P. yoelii (ART) single dose comparisons of WP and AN 
treatments: WPLO (N=6) and WPHI (N=6) received in planta artemisinin at 24 mg/kg and 
120 mg/kg, respectively; ANLO (N=6) and ANHI (N=6) received pure artemisinin at 24 
mg/kg and 120 mg/kg, respectively. Placebo control (CON, N=5) received only mouse 
chow. Dark lines indicate average parasitemia by treatment type. Lighter lines show 
individual mouse trajectories. Shaded regions indicate the 95% confidence interval for 
the means calculated based on normality assumptions. Arrow indicates time of treatment 
 
Having demonstrated that WP is effective against artemisinin-resistant parasites, 
we conducted an artificial evolution experiment to compare rates at which resistance to 
these two modalities arose among wild-type parasite lines. Using the 2%-relapse 
technique for long-term selection of drug resistance in Plasmodium chabaudi parasites, 
we achieved stable resistance to 100mg/kg AN at passages 13-16. On passage number 17, 
the dose was increased to 200mg/kg AN. Parasites acquired tolerance to this double dose 
after 40 passages with constant delay time less than 25% of the first passage (Fig. III.3). 
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The comparable dose of WP (100mg/kg AN) was more resilient such that 
resistance was achieved after only 45 passages.  The WP treatment of 100mg/kg was 
even more resilient than the doubled dose (200mg/kg) of pure AN in the second phase of 
selection. P. chabaudi generally develops resistance to antimalarial drugs faster than 
other rodent malaria species (113). In a similar selection study using a combination 
therapy of artesunate 30mg/kg/day + mefloquine 5mg/kg/day- given over three days, 
resistance was achieved after 27 passages (116). Just as ACT treatment is more resilient 
Fig. III.2: AN-resistant P. yoelii (ART) curative treatment: Mice were infected with P. 
yoelii (ART) and treated with either pure artemisinin (N=6) at 120 mg/kg, or WP in 
planta artemisinin (N=6) at 120 mg/kg. Mice were treated for 9 consecutive days 
starting on day 2 post-infection. ** = P < 0.01. Error bars represent SD.  
** 
** 
** ** 
** 
** 
** 
** ** ** 
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than a purified AN (117), we contend that WP treatment is more resilient than a 
pharmaceutical AN because WP treatment contains multiple and complementary 
compounds effective in killing malaria parasites including those resistant to 
pharmaceutical AN. 
A. annua extracts have a number of different practical uses in agriculture and 
public health.  These include repellency against stored product beetles (118), larvicidal 
activity against Anopheles stephensi (119), insecticidal activity against elm leaf beetle 
(120), and use as an acaricide (121). Moreover, AN and its derivatives have also shown 
to have effects on a number of viruses replication, a variety of human cancer cell lines 
(35, 36), several neglected tropical parasitic diseases including schistosomiasis (44), 
leishmaniasis (45, 46), New- and Old-World trypanosomiases (47), and many livestock 
diseases (48).  
To better understand the reasons for efficacy of phytochemicals in killing 
mammalian parasites, we must consider carefully plant biology and evolution. Like all 
plants, A. annua lacks an immune system that can adapt somatically to its natural enemies 
including viruses, bacteria, fungus, parasites, insects and other animals.  Instead of an 
acquired adaptive immune response, plants possess a complex repertoire of chemical 
defenses against a wide range of organisms. Evolutionarily successful plant species such 
as A. annua possess large arrays of bioactive compounds providing resilient protection 
against micro and macro threats (122) (123). The bioactive secondary metabolites of A. 
annua are synthesized and stored in glandular trichomes, which are small cusps of 
epidermal origin consisting of differentiated basal, stalk, and apical cells.  Trichomes are 
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specialized to synthesize, store, and secrete large amounts of phytochemicals including 
artemisinin, flavonoids, phenolics and terpenoids  (123-125). 
 
 
 
Components of the A. annua chemical defense include allelopathic factors that 
inhibit neighboring plants from germinating or growing. Artemisinin is known to have 
potent herbicidal activity acting on the electron transport in chloroplast membrane (124) 
Fig. III.3. Evolution of resistance in P. chabaudi (ASS) exposed initial 
dose of 100 mg/kg AN (upper blue line), then increased (Arrow) to 200 
mg/kg AN (upper red line) and WP 100 mg/kg in planta artemisinin ( 
lower blue line) , following the 2% relapse technique.  
  
	  57	  	  
and plant cell membrane (39, 126). That these defenses are also effective at killing a 
mammalian blood-borne parasite seems at first coincidental, however there is a plausible 
evolutionary explanation for this cross species protection. Malaria parasite cells contain 
apicoplasts, which were derived initially from the same ancestral cyanobacterial 
endosymbiont that gave rise to chloroplasts in plants (127).  This vestigial organelle in 
Plasmodium is believed to be an essential target of the A. annua allelopathy defense 
mechanisms (38).  
It is well known that the bacterial origin of apicoplasts renders malaria parasites 
susceptible to antibiotics, such as doxycycline, which have known to inhibit transcription 
and translation of prokaryotes by blocking its replication and malaria parasite cell death 
(127, 128). Likewise, the presence of plant-like organelles and pathways in parasites that 
are absent in the human host present intriguing prospects for co-opting herbicidal 
compounds as medicaments(129). Various plant extracted herbicides already have been 
found to have specific parasite killing activity against apicomplexan parasites including 
P. falciparum, Cryptosporidium parvum and Toxoplasma gondii (38). These herbicides 
may be synthetic or, as with the WP therapy discussed here, derived from naturally 
occurring plant forms.  
Among the phytochemical repertoire that is synthesized and located in the 
trichome are the terpenoids, the essential oil constituents of A. annua giving the plant its 
fragrance (101). Terpenoids are compositions of component isoperenes with extensive 
branching and cyclization ability. Plasmodium spp. possesses its own terpenoid pathways 
present with the apicoplast which is essential for the growth and replication of intra and 
extra erythrocytic stages (130) (128). Due to similarity among the intermediates of plant 
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and parasite pathways, some of the plant derived terpenoids have been shown to disrupt 
function of the apicoplast leading to parasite killing (131). Among the anti-parasitic 
terpenoids is nerolidol that inhibits the biosynthesis of the isoprenic chain (132) and 
limonene that inhibits the protein isopenylation in the erythrocytic stages of P. 
falciparum (133). Nerolidol, linalool, limonene and farnesol have IC50 against P. 
falciparum of 760 nM, 0.28mM, 1.22mM and 64uM, respectively (134). Monterpenes 
isolated from eucalyptus oil (80% cineole) inhibit chloroquine-resistant and chloroquine-
sensitive P. falciparum by mechanisms believe to be connected to membrane disruption 
(135). Indirect evidence of other non-AN antimalarial activity in A. annua is provided the 
documented parasite killing using related species of Artemisia that do not produce 
artemisinin (67).  Moreover, several other sesquiterpenes in A. annua have shown activity 
against malaria parasites (67). The ability of plants to produce a virtually unlimited 
diversity of terpenoids by elongations, cyclizations, and rearrangements gives potential 
for redundant and resilient anti-parasite killing activity (11, 136)  
As in the challenge experiments against malaria parasites, the allelopathic activity 
is higher for the whole plant than a comparable dose of its pure extract AN when 
incorporated into soil (137). The higher allelopathic activity of whole plant A. annua than 
its pure extract AN is attributable to the synergism among A. annua constituents (137) 
and/or the presence of other constituents of A. annua that have potent herbicidal activity 
(37). This same synergism between A. annua constituents has been reported to potentiate 
the antimalarial activity against P. falciparum (14, 41, 48, 67). 
The fact that antimalarial activity of WP is better than artemisinin can possibly be 
explained by enhanced bioavailability of artemisinin due to inhibitory effects of some A. 
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annua flavonoids on the hepatic and intestinal cytochrome P450 enzymes that metabolize 
artemisinin (66, 83). Plant material seemed to enhance by >40 fold the amount of 
artemisinin that entered the blood stream (49). The presence of plant material in mouse 
chow significantly increased the amount of artemisinin that appeared in the serum (83). 
Whole plant A. annua may also have increased activity against malaria parasites 
due to the synergism among some key flavonoids and artemisinin (14, 41, 48, 67) or by 
the antimalarial activity of other A. annua constituents independent from AN. Certain A. 
annua flavonoids (artemetin, casticin, chrysosplenetin, chrysosplenol-D, cirsilineol, and 
eupatorin) showed antimalarial activity against P. falciparum in the absence of AN (138).  
Similarly, four dietary flavonoids—kaempferol, quercetin, apigenin and luteolin—that 
are present in A. annua (101) were tested against chloroquine-sensitive  P. falciparum 
(strain 3D7) and showed 50% Inhibitory Concentrations (IC50 ) of 33uM, 15uM, 20uM 
and 11uM, respectively. Also, these four flavonoids were effective against chloroquine-
resistant P. falciparum (strain 7G8) giving IC50 of 25uM, 14uM, 13uM and 12uM, 
respectively. Similarity of IC50 values for each of these four flavonoids regardless of their 
chloroquine sensitivity suggests that the flavonoids are acting on targets distinct from 
those of chloroquine.   
The likelihood of developing resistance is greater for a single antimalarial 
compound than a combination therapy. Increased resilience of WP relative to a 
comparable dose of pharmaceutical AN is consistent with this pattern.  Resilience of WP 
can be explained by the presence of a large phytochemical repertoire of small molecules 
that target many active enzymatic sites essential for malaria parasite survival and growth, 
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making it more difficult for parasites to accumulate necessary resistance mutations in the 
ensemble of genes responsible for encoding those essential target sites.  
The 19th century conceptualization of “magic bullets” led us to the serial use of 
monotherapies that blindly select for resistant micro- and macro-organisms throughout 
the 20th century. The benefits realized in roughly the first half of that period in medicine 
and agriculture were undone in the latter half by proliferation of resistance to antibiotics, 
antimalarials, insecticides and herbicides. A renewed appreciation for evolution and the 
adaptive potential of the targeted organisms has lead to more sustainable approaches 
using combinations of control agents. The success of the combinatorial approach is 
evidenced throughout nature, and A. annua is a prime example with its repertoire of 
several hundred compounds comprising that plant’s defense system. If plants had 
followed the pharmaceutical model of serial production of single component protection 
against its enemy, they would gone extinct long ago (14).  The WP anti-malarial therapy 
serves as a case study of how those resilient naturally occurring systems might be co-
opted for human use. While much work remains, the clear evidence of the efficacy of WP 
as a naturally occurring combination therapy pACT warrants its further consideration to 
explore how we might develop inexpensive, abundant and resilient malaria therapies 
from a non-pharmaceutical product.  
Conclusions 
Emergence of artemisinin-resistant malaria parasites raises urgent need for 
alternative treatment that is affordable, resilient and effective against resistant parasites.  
In our previous study we reported that antimalarial activity of whole plant Artemisia 
annua was at least 5 times more effective than an equivalent dose of its pure extract AN 
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(41). Here we also show that dried whole plant material of A. annu is more effective in 
killing malaria parasites resistant to AN.  We’ve also shown that WP is more resilient 
than pharmaceutical AN and may actually delay the onset of resistance.  While the exact 
mechanisms still need to be identified, the antimalarial activity of WP against 
artemisinin-resistant parasites can be explained by increased bioavailability of AN, 
synergism among AN and some A. annua constituents and/or the presence of other 
compounds in A. annua that may have antimalarial activity independent from AN. The 
efficacy and resilience of A. annua-based WP treatment against rodent malaria provides 
compelling reasons to further evaluate the role of non-pharmaceutical forms of AN to 
treat human malaria.  
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Introduction: 
 Babesiosis is a tick-borne disease caused by haemotropic apicomplexan protozoa of 
the genus Babesia, which are transmitted mostly by Ixodes ticks but also by blood 
transfusion and prenatally(28, 139-143). After trypanosomes, Babesia is the most 
common mammalian blood parasite (140). Like Plasmodium, Babesia invades 
erythrocytes, has an invertebrate vector, and the symptoms of the two diseases are 
similar, including fever, flu-like symptoms, chills, headache, anemia, hemoglobinuria, 
and myalgia. In regions where malaria is endemic, co-infection with Babesia parasites 
has been observed, and babesiosis may be misdiagnosed as malaria (27).  
The life cycle of Babesia requires a tick vector for sexual reproduction and 
transmission to the vertebrate host. After gametogenesis in the tick midgut, the motile 
embryo replicates in ovaries and salivary glands. Sporozoites in the salivary glands are 
transmitted to vertebrate hosts parasitized by ticks, while ookinetes in ovarian cells are 
transmitted to the tick's offspring (28). Unlike Plasmodium and Theileria, babesial 
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sporozoites directly invade erythrocytes without the need for replication in hepatocytes 
(Plasmodium) or lymphocytes (Theileria).  
To date, seven species of Babesia have been found to cause human babesiosis: 
Babesia microti, B. divergens, B. bovis, B. canis, B. duncani, B. venatorum and Babesia 
KO1 (28).  Babesia has been diagnosed in  increasing numbers of humans in recent years 
due to greater medical awareness and increased numbers of immunocompromised 
patients (28). Because Babesia has historically been a disease of domestic animals, 
current antibabesial pharmaceuticals may be licensed only for veterinary, but not human 
use (28). The lack of routine treatment for Babesia and the similarity between Babesia 
and Plasmodium triggered drug development investigators to test antimalarial drugs 
against different species of Babesia (144). The combination of quinine and clindamycin 
was effective in treating human and animal cases. However B. microti infections 
persisted after treatment and adverse reactions to treatment were reported in about 25% 
of all treated cases (145) (146, 147). Immunocompromised patients are usually treated 
with a combination of atovaquone and azithromycin, but relapses after prolonged 
treatment suggested that B. microti readily evolved resistance to these compounds (148). 
Resistance against atovaquone, another common antimalarial, was reported in hamster B. 
microti (149). The lack of effective treatment for human babesiosis, particularly in 
immunocompromised patients, creates an urgent need for new antibabesial therapeutics. 
The difficulty of distinguishing malarial and babesial infections and the frequent co-
infections with the two diseases create the need for cost-effective treatments that combat 
both diseases.  
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Artemisinin, extracted from the herb Artemisia annua, is currently the preferred 
treatment against malaria. To delay the onset of drug resistance, the World Health 
Organization (WHO) recommended using artemisinin or its derivative, artesunate, in 
combination with other antimalarial drugs, lumefantrine or mefloquine, in a treatment 
known as Artemisinin Combination Therapy (ACT)(42). Beside antimalarial activity, 
artemisinin and its derivatives have also shown efficacy against a number of viruses, 
human cancers (35, 36), schistosomiasis (44), leishmaniasis (45, 46), trypanosomiases 
(47) and possibly babesiosis (150).  
At concentrations ≥ 2.6 µM, Goo et al. (2010) showed that, artesunate inhibited the in 
vitro growth of B. bovis the causative agent of bovine babesiosis, but to inhibit B. gibsoni 
the causative agent canine babesiosis, the concentration had to be raised 100-fold to 260 
µM (150). In contrast in mice infected with B. microti, an intramuscular treatment of 50 
mg kg-1 artesunate delayed, but did not completely quell parasitemia.  
Recently, using a rodent malaria model P. chabaudi, we showed that oral 
consumption of powdered dried leaves of A. annua (100 mg artemisinin kg-1 body 
weight) inhibited parasitemia at least five-fold more than pure artemisinin (41). Plant 
material seemed to enhance by >40 fold the amount of artemisinin that entered the blood 
stream (49). There are many other compounds in the plant that may account for the 
enhanced efficacy of orally consumed dried A. annua leaves and thus, we have called this 
treatment plant Artemisinin Combination Therapy, pACT.  Such a therapy would also be 
more cost effective than current ACTs saving the cost of artemisinin isolation and 
purification. Beside malaria, pACT represents a candidate treatment against many other 
diseases susceptible to artemisinin and its derivatives. 
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In light of the earlier study by Goo et al. (2010) and the potent activity of pACT 
against malaria (150), we hypothesized that pACT may also have enhanced activity 
against B. microti, the   cause of most of human cases in the United States. The objective 
of this work was to compare the therapeutic effects of pACT to those of the pure 
compounds, artemisinin and artesunate, in a murine model of B. microti infection. We 
hypothesized that the increased bioavailability of artemisinin from the whole-plant 
material, combined with the possible additive and synergistic effects of other plant 
compounds, could make whole-plant therapy more effective against babesiosis than 
treatment with individual compounds. 
 
Materials and Methods: 
Treatments: Artemisia annua L. (SAM cultivar; voucher MASS 00317314) containing 
1.48±0.06% artemisinin, 0.37% flavonoids, monoterpenes (e.g., 0.21% (w/w) camphor, 
0.007% eucalyptol, 0.037% α-pinene) as determined by GC-MS was used in this study. 
Plants were grown, harvested, dried, and leaves sieved and pulverized as previously 
described (41). Artemisinin (AN) and artesunate (ART) were purchased from Sigma 
Aldrich.  
Parasite information: Cryopreserved isolates of Babesia microti were kindly provided 
by Samuel Telford (Tufts University). To revive the parasites, cells were intraperitoneally 
injected into two inbred male DBA/2 mice. The revived parasites were used in 
subsequent experiments.  
Mouse infection and feeding details: To test the effects of artemisinin intake on 
parasitemia, inbred male DBA/2 mice 12 weeks old were intraperitoneally injected with 
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107 infected red blood cells and randomly divided into four treatment groups: AN, ART, 
pACT and CON (control) with eight mice in each group. Beginning two days after 
parasite inoculation, mice were treated daily for six days via oral gastric gavage with 
100mg/kg mixed with a water slurry of mouse chow containing either AN or ART and 
water slurry of dried ground A. annua leaves (pACT) corresponding to 100mg AN /kg 
body weight. Mice in the CON group were gavaged a placebo consisting of water slurry 
of mouse chow only. Detailed information about mouse feeding, drug preparation and 
parasitemia count can be found in Elfawal el al (2012)(41). Parasitemia was measured 
daily on Giemsa-stained thin blood smears and mice were euthanized on day17 post 
inoculation (Fig. IV.1).  
Ethics Statement: This study was carried out in strict accordance with the 
recommendations in the Guide for the Care and Use of Laboratory Animals of the 
National Institutes of Health. The protocol was approved by the Institutional Animal Care 
and Use Committee (IACUC) of the University of Massachusetts (Protocol# 2011-0072). 
All efforts were made to minimize suffering of animals during experimental procedures. 
 
Results and discussion  
We compared the antibabesial activity of a whole-plant (pACT) to that of pure 
compounds used in conventional malaria treatment (AN and ART). Parasites were found 
in blood of infected mice 48 hours after inoculation. Days 2-7 post-inoculation, 
parasitemia increased, peaking on day 11; this was 4 days after cessation of treatments in 
all groups. Parasitemia declined on days 12-14 post inoculation, then increased again on 
day15 post inoculation (Fig. IV.1). Mice were euthanized 17 days post-inoculation when 
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parasites were found in about 15% of erythrocytes.  The course of infection was similar 
to that previously observed in Babesia microti-infected mice (150, 151). None of the 
treatment groups showed significant reduction in parasitemia in comparison to controls 
treated with water slurry of mouse chow (Fig. IV.1).  
 
 
Fig. IV.1: B. microti mean of daily parasitemia of four treatment groups: whole 
plant A. annua corresponding to 100mg/kg (pACT), artemisinin 100mg/kg (AN), 
artesunate 100mg/kg (ART) and placebo control (CON). Mice were treated once daily for 
six days via oral gastric gavage starting two days post intraperitoneally infection with 107  
parasite-infected red blood cells. Means of daily parasitemia were analyzed for statistical 
significance by analysis of variance. P >0.05 was considered to be statistically not 
significant.   
The lack of effective antibabesial drugs and the similarity between Babesia and 
Plasmodium in biology and disease symptoms have led to the testing of antimalarial 
compounds against different species of Babesia (144). Chloroquine was the first 
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antimalarial drug tested against human babesiosis without success (145, 152). Following 
chloroquine many antimalarial compounds were tested and found to be ineffective 
against Babesia microti including artesunate, mefloquine and halofantrine (144, 149, 
153). In contrast, artesunate was found to be partially effective in controlling Babesia 
microti and to delay the peak of parasitemia during treatment days, but it failed to 
eradicate the disease or to control parasitemia levels that reached 19% and 24% only 5 
days after the last treatment of 10mg/kg and 50mg/kg, respectively (150).    
Artemisinin is a sesquiterpene lactone with a peroxide bridge that is responsible 
for its antimalarial activity (154-156). The mode of action of artemisinin is under 
considerable discussion with several proposed modes of action. One is interference with 
digestion of hemoglobin by the parasite.  Hemoglobin digestion yields toxic heme, but 
the parasite forms crystalline polymers of insoluble nontoxic hemazoin in the digestive 
vacuole. This mode of action, however, conflicts with reported activity of artemisinin 
against younger stages of the malaria parasite and other parasites that lack hemazoin 
synthesis and a digestive vacuole (157). A second possible mechanism for artemisinin 
mode of action is through cleavage of its peroxide bridge by heme, producing a carbon-
centered free radical that alkylates, modifies and inhibits essential parasite molecules thus 
resulting in parasite death (154-156). A third alternative proposes direct interaction 
between artemisinin and the SERCA-like Ca+2 –PfATP6 calcium pump present in 
Plasmodium; mutation in the PfATP6 gene is associated with artemisinin resistance (156, 
158, 159). Iron-containing molecules are essential for enhancing artemisinin-PfATP6 
binding and the heme-artemisinin complex interacts well with PfATP6 causing 
modification in its molecular structure preventing calcium binding, leading to disruption 
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of the SERCA-like pump (156).   Iron containing molecules known to enhance 
artemisinin activity by enhancing PfATP6 activity and other free radicals include heme 
(154, 160-163), hemin (68, 162), denatured hemoglobin in the digestive vacuole (154) 
and inorganic iron (164). When these four iron sources were tested for their ability to 
activate artemisinin, heme was the best; inorganic iron was ineffective (154).  In malaria 
heme is produced de novo in the apicoplast, the plastid-like organelle exclusive to 
apicomplexan parasites and involved in biosynthesis of heme, fatty acids, and isoprenoid 
precursors.  The antimalarial activity of artemisinin may be increased additively by the de 
novo synthesized heme.  
The intracellular parasite B. microti has a single membrane without a 
parasitopherous vacuole. The importance of the second membrane and the 
parasitopherous vacuole seems to be in host parasite interaction and forming the digestive 
vacuole, the main target for many antimalarial drugs, where hemoglobin digestion takes 
place. It has been suggested that in contrast to malaria, B. microti invades erythrocytes 
using a mechanism other than membrane invagination (165). Although in Babesia the 
double membrane is absent in mature trophozoites, it is present in the young merozoites 
shortly after invasion thereby confirming that B. microti invades erythrocytes by 
invagination like Plasmodium, but with rapid degradation of the second host membrane 
shortly after penetration. A similar phenomena was observed in Eimeria manga (165). 
Such a rapid degradation of the second membrane suggests a unique interaction with host 
cells in obtaining nutrients and hemoglobin digestion (165, 166).   
In further contrast to Plasmodium, B. microti has a highly polymorphic 
intracellular stage with pseudopods forming host cytoplasm invaginations. Such 
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invaginations were believed to be a digestive vacuole. However liberated parasites from 
host cells were found to have vacuole-like structures lacking host cytoplasm (165, 166). 
The absence of a digestive vacuole was confirmed using electronic microscope imaging 
of different sections of the intracellular parasites showing invagination of the host 
cytoplasm forming what is named pseud vacuole (165, 166).  
The lack of a parasitopherous vacuole, a digestive vacuole, and hemazoin 
formation in Babesia parasites has led to contrasting conclusions about the ability of 
Babesia to digest hemoglobin. One opinion suggested that Babesia may completely 
digest hemoglobin extracellularly without hemazoin formation and by unknown 
mechanisms (167). On the other hand, it was also suggested that Babesia parasites may 
not even digest hemoglobin (165, 166). The latter conclusion was recently supported by 
sequencing the whole genome of B. microti and surprisingly, among all apicomplexan 
parasites B. microti has only three nuclear chromosomes, its overall genome size is about 
72% smaller than P. falciparum, and it lacks hemoglobin proteases (139).   
In a molecular phylogenetic study using the full sequence of 316 genes, B. microti 
was placed as paraphyletic group that was a root for all Babesiidae including both 
Babesia and Theileria. Such a result confirmed the distinction between B. microti and 
other piroplasms and suggested the need for creating a new genus for B. microti (139); 
(168).  
The increased surface area of the parasite with intra-erythrocytic polymorphic 
shapes (pseudopods, whirls, and pseudo vacuole), the absence of the double membrane, 
the absence of parasitopherous vacuole, the absence of hemoglobin proteases, and the 
low metabolism of this parasite suggest that B. microti is highly dependent on the host 
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red blood cell for obtaining nutrients by diffusion through its single membrane (165, 
166). Dependence on host cells in obtaining essential amino acids is not a feature unique 
to Babesia; P. falciparum also depends on host cells to obtain essential amino acids 
unavailable from hemoglobin digestion (169). In contrast to apicoplast function in 
Plasmodium that also synthesizes heme and fatty acids, apicoplast function in B. microti 
is limited to synthesis of isoprenoid precursors and lacks heme biosynthesis (139). The 
absence of the digestive vacuole and heme biosynthesis in Babesia may explain the lack 
of activity of artemisinin or artesunate against B. microti. However, although Toxoplasma 
gondi lacks hemazoin, digestive vacuole and hemoglobin digestion, it is still susceptible 
to artemisinin. The anti-parasitic activity of artemisinin against T. gondi may be 
explained by the de novo heme synthesized in its apicoplast. On the other hand, 
artemisinin and its derivatives failed to control infection of Cryptosporidium parvum in 
neonatal mice (170) and in in vitro culture (171). Among all apicomplexan parasites, only 
C. parvum lacks the apicoplast. C. parvum also lacks the digestive vacuole and 
hemoglobin digestion. The lack of artemisinin activity against C. parvum may be 
explained by the lack of enough heme concentration either from hemoglobin digestion (as 
in Plasmodium) or de novo synthesized (as in Plasmodium and Toxoplasma). Despite B. 
microti harboring the apicoplast, that function is limited to isoprenoid synthesis, it lacks 
both sources of heme. Thus, artemisinin and its derivatives failed to control infection in 
B. microti similarly to C. parvum. In conclusion, the anti-parasitic activity of artemisinin 
is dependent on enough heme concentration within the parasite.   
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The antimalarial activity of pACT is better than artemisinin and is possibly 
explained by enhanced bioavailability of artemisinin due to inhibitory effects of some A. 
annua flavonoids on the hepatic and intestinal cytochrome P450 enzymes that metabolize 
artemisinin (83). In contrast, enhanced generation of heme does not seem to occur in B. 
microti, so greater bioavailability of artemisinin from pACT is moot.  
 Enhanced antimalarial activity of pACT is also potentially explained by the possible 
synergism between artemisinin and one or more other constituents in A. annua including 
terpenes, phenolic acids and flavonoids, (14, 48, 67, 172). For example, flavonoids were 
shown to reduce the IC50 of artemisinin against P. falciparum (41, 57, 58). Although not 
fully understood, methoxylated flavonoids enhanced formation of the artemisinin-heme 
complex, which reportedly enhances artemisinin binding to SERCA-like calcium pump 
and cleavage of the peroxide bridge releasing free radicals (68). The absence of anti-
babesial effects by Artemisia annua and its chemical components may reflect the 
differences in artemisinin drug targets between Babesia and Plasmodium.  
 
Conclusion:  
Human babesiosis is an emerging disease caused by a parasite distinct from all 
apicomplexans. The disease particularly affects immunocompromised people in 
developing nations where malaria often co-infects and new treatments are urgently 
needed.  Although reported to be effective for other Babesia sp., and in contrast to 
Plasmodium sp., none of the three forms of artemisinins tested here seem effective 
against B. microti. The differential response of Babeisa sp. to artemisinins is likely the 
result of significant differences in their cell biology and metabolism of hemoglobin.  The 
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apicoplast of both Plasmodium and Babesia has the nonmevalonate isoprenoid anabolic 
pathway, which is susceptible to fosmidomycin, so this antibiotic could be used to treat 
patients with malaria-Babesia co-infections. Although effective against malaria, some 
Babesia species, and a number of other apicomplexans, neither pACT nor artemisinin and 
artesunate are effective against B. microti, so the search for new therapeutics against this 
debilitating disease must continue. 
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FINAL CONCLUSIONS 
Plant antimicrobial secondary metabolites are complex multicomponent matrices 
with synergy among their components and biological activity against a broad spectrum of 
microbes through a variety of mechanisms (13, 14, 173). During their own coevolution 
with pathogens, animals evolved self-medication behavior relying on direct ingestion of 
plant matrices of antimicrobial secondary metabolites which, when directly ingested, 
could treat or prevent diseases. Plants have limitless ability to synthesize secondary 
metabolites, which serve as plant defense against predation by microorganisms, insects, 
and herbivores (174). Secondary metabolites give plants their odor, flavor and pigment. 
Plants generate several categories of secondary metabolites: phenolics (simple phenolics, 
quinones, flavonoids, tannins, coumarins), terpenoids, alkaloids and polypeptides (174). 
The medicinal properties of plants come from the interactions of multiple constituents, 
and its overall properties may never be completely achieved by using their component 
parts (14).  These interactions in medicinal plants are known as synergy, when the effect 
of the combination is greater than the sum of the individual effects (14).   Crude extracts 
from many medicinal plants were found to be effective against viruses (175-179), 
bacteria (180-185), protozoa (186, 187), helminths (188-190) and fungi (180, 182, 191). 
Such antimicrobial properties are made of small molecules that fit into sites in enzymes 
or receptors essential for pathogens survival. Because pathogens tend to develop 
resistance, many of the plant’s secondary metabolites are developed to inhibit resistance 
mechanisms (192).  
About 25% of prescribed drugs and about half of newly discovered drugs are 
from plant origin (193), and about 80% of the world population relay on plant-derived 
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medicines (173, 194).  But current pharmaceutical industry strives to isolate single active 
compounds (195), and thus may overlook many useful complex secondary metabolites 
with potential synergistic antimicrobial activity.  
 Use of single-target monotherapeutic drugs tends more often to select for micro- 
and macro-organisms resistance, whether that resistance is to antibiotics (196), 
antiparasitic (110), insecticides (197), and herbicides (198). Prolonged use of 
antimicrobial monotherapy leads to the evolution of drug resistance in microorganisms 
that initially were sensitive but gradually adapt and develop resistance.  Repeated use of 
antimicrobial agent selects for resistant and select against sensitive microorganisms. 
Microorganisms achieve drug resistance through number of mechanisms, including 
reduction in drug uptake through efflux pumps, avoiding drug activity by drug 
degradation or alteration, increased expression of drug target, decrease binding ability of 
drug due to modification in its target (196, 199-201). Drug resistance can be innate to 
microorganisms or acquired through mutation and horizontal gene transfer (196, 200). 
Resistance-associated mutations are likely to be deleterious because they result in 
metabolic pathway modification (200). The development of new mutation depends on 
mutation rate and fitness cost, thus resistance-associated mutations are less favored or 
costly in absence of the selective drug.  If resistance phenotype requires two mutations, 
the initial frequency of organisms harbor these two mutations is much lower than the 
frequency of organisms harbor only one mutation. Thus the likelihood of developing drug 
resistance to a combination therapy is much lower than developing resistance to 
monotherapy (202). Similarly the likelihood of developing resistance to single compound 
that require more than one mutation is much lower than those require single mutation. 
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Combination therapy may delay the evolution of drug resistance more than monotherapy 
(202), however if multiple compounds are actively target the same site, single mutation 
may lead to resistance to combination of these compounds (110).  
Herbal remedies have been used for several thousands of years, but resistance 
does not seem to have appeared. In contrast isolated or synthetic compounds have 
suffered from the appearance of resistant microorganisms. Matrices of secondary 
metabolites are evolutionary designed to be effective against microorganisms using 
hundreds of small molecules that target sites of multiple enzymes and receptors essential 
for microorganisms (14). Such strategy of using synergic multicomponent defense system 
enabled plants to thwart microorganism’s ability to develop resistance. Using complex 
matrix of secondary metabolites by plants, microorganisms fall easy target for such 
complexity, and to develop resistance against single component microorganisms will be 
more vulnerable against others. Synergic activities of secondary metabolites were found 
to enhance activity against resistant pathogens including bacteria (185, 203, 204) and 
protozoa (14, 41, 48, 205).     
Because it is almost impossible to generate hundreds of resistance-associated 
mutations at once, against multiple repertoires of secondary metabolites, microorganisms 
had to develop multidrug resistance involving protein pump located on cell membrane 
throwing foreign molecules out of the cell. Facing similar matrixes of secondary 
metabolites many microorganisms convergently develop MDR including bacteria (196), 
protozoa (110), fungi (206), and viruses (207).  In response to MDR, plants co-evolve 
and produce secondary metabolites that are specialized to disrupt MDR.  Phytochemicals 
from many plant species were found to be effective against multidrug resistant pathogens.  
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Crude leave extracts from Lantana camara L. were found to be effective against three 
multidrug resistant Gram-positive bacteria: Methicillin-Resistant-Staphylococcus aureus 
(MRSA), Streptococcus pyrogenes, and Vancomycin-Resistant-Enterococcus faecalis 
(VRE); and five B-lactamase producing-Gram-negative bacteria: Acinetobacter 
baumannii, Citrobacter freundii, Proteus mirabilis, Proteus vulgaris and Pseudomonas 
aeruginosa. Dichloromethane extract had the most antibacterial activity against MRSA 
with lowest Minimum Inhibitory Concentration (MIC), followed by methanol extract. On 
the other hand the lowest antibacterial activity with highest MIC was observed in water 
extract (208). Phytochemical analysis of dichloromethane extract approved the presence 
of alkaloids, glycoside, terpenoids, saponins, flavonoids, tannins, and steroids. On the 
other hand methanol extract lack tannins and glycosides. It was concluded that the more 
secondary metabolites in extract the more antibacterial activity against bacteria (208).  
Similarly extracts from Lygodium flexuosum L. were found to be effective against MDR-
MRSA and –VER (209). Alkaloids from Meconopsis simplicifolia were found to be 
effective against MDR-K1CB1 P. falciparum (210). Extracts from Mangifera indica 
leaves and bark were found to be effective against MDR-Dd2 P. falciparum (205).  
Here we found dried whole plant (WP) Artemisia annua is at least five times more 
effective than purified compounds in killing malarial parasites.  Moreover WP overcomes 
artemisinin-resistant malaria parasites. Moreover, whole plant A. annua was at least three 
times more resilient against the evolution of drug resistance than purified artemisinin.  
Enhanced pharmacokinetic and pharmacodynamic properties of whole plant A. annua 
compared to purified artemisinin may be explained by the presence of a complex matrix 
of secondary metabolites, some of which increases the bioavailability of artemisinin by 
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inhibiting hepatic and intestinal enzymes that degrade artemisinin.  This was supported 
by our observation that plant material such as that found in mouse chow was critical to 
the appearance of artemisinin in the blood of orally-treated mice. The pharmacokinetic 
properties of artemisinin delivered in planta were also different between uninfected and 
infected mice.  Enhanced antimalarial activity of A. annua over artemisinin can be 
explained by the presence of A. annua constituents with antimalarial activity independent 
from artemisinin, including flavonoids and terpenes other than artemisinin. Alternatively, 
non-artemisinin A. annua constituents with antimalarial activity may depend on the 
synergistic effects of artemisinin to realize their parasite-killing potential.  
Use of dried whole plant A. annua directly against malaria could dramatically 
decrease the cost of therapy, giving hope to millions of people living in malaria endemic 
regions. Because chemical synergism in the plant chemical matrix is common in 
medicinal plants, we speculate that many whole plants material will show increased 
bioactivity compared to compounds purified from them.  Using plants in their whole form 
will decrease drug production costs and eventually reduce healthcare costs.  
Creating greater opportunity for use of whole plant therapy to fight human 
diseases, no less than three fundamental paradigm shifts must occur in how the 
pharmaceutical enterprise approaches use of whole plants in drug development.  
The first shift must be to alter the objective for using plant derived compounds 
themselves.  Currently, the convention is to use purified compounds, thus relying on very 
costly drug purification processes (194).   Because we showed that whole plant A. annua 
is more effective than a purified compound, we suggest testing the clinical efficacy of 
whole plants, not simply their purified extracts. Using the whole plant directly, thereby 
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maintaining its matrix of secondary metabolites, may have the added benefit of delaying 
evolution of drug resistance as we’ve found here, thus saving many drugs from premature 
obsolescence. 
Second will be new approaches to plant breeding programs. Currently, breeding 
programs are designed to create crops that yield increased concentration of a single 
compound without regard to beneficial effects of many other plant constituents (211). We 
suggest an alternative breeding strategy that selects plants for their optimal biologically 
active phenotype. The goals would be to maintain the complex and diverse repertoire of 
secondary metabolites and buffer associated synergies that require their co-isolation.  
The third paradigm shift would be in the field of drug discovery. Current drug 
discovery strategies most often follow simplistic models, testing activity of individual 
purified compounds isolated from medicinal plants but ignoring synergism between plant 
constituents(194). This archetypal approach neglects the effects of compounds that may 
not show any activity when tested individually. Simple drug discover models were 
exclude many important compounds from recognition because often the therapeutic does 
exceed the toxicity dose of those single compounds. We suggest an alternative approach 
that uses advanced computational and laboratory tools-- high-throughput screening to test 
millions of combinations for potential antimicrobial activity-- to build complex 
combinatorial models incorporating synergisms, antagonisms and other interactions 
among plant components. More research is needed on the pharmacodynamics and 
pharmacokinetics synergy, resistance reversal, and immunomodulation properties of 
medicinal whole plants including toxicity studies and clinical research.  
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